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ATTIVITÀ DI RICERCA 
 
Durante il Dottorato di Ricerca mi sono occupato dello studio della regolazione genica in 
Neisseria meningitidis. In particolare, ho studiato la risposta in termini di espressione genica alla 
disponibilità di glucosio, identificando un regolatore trascrizionale HexR che coordina il 
metabolismo centrale di meningococco. Ho caratterizzato le interazioni molecolari tra la 
proteina HexR e i suoi geni target, e ho studiato l’impatto della regolazione mediata da HexR 
sulla capacità di N. meningitidis di causare batteremia in un modello murino di infezione. 
In parallelo, ho indagato il ruolo dei piccoli RNA non codificanti nella regolazione genica di 
meningococco. Tramite sequenziamento dell’RNA ad alta risoluzione ho identificato e mappato 
nuovi trascritti potenzialmente regolatori, e ho studiato l’impatto di candidati selezionati sulla 
batteremia di N. meningitidis. Infine, ho iniziato la caratterizzazione molecolare di un nuovo 
piccolo RNA unico di meningococco, strettamente associato a geni rilevanti per le Neisseriae 
patogene. 
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1 Abstract 
Neisseria meningitidis, the leading cause of bacterial meningitis, can adapt to different host 
niches during human infection. Both transcriptional and post-transcriptional regulatory 
networks have been identified as playing a crucial role for bacterial stress responses and 
virulence. We investigated the N. meningitidis transcriptional landscape both by microarray 
and by RNA sequencing (RNAseq).  
Microarray analysis of N. meningitidis grown in chemically defined medium in the presence 
or absence of glucose allowed us to identify genes regulated by carbon source availability. In 
particular, we identified a glucose-responsive hexR-like transcriptional regulator in  
N. meningitidis. Deletion analysis showed that the hexR gene is accountable for a subset of 
the glucose-responsive regulation, and in vitro assays with the purified protein showed that 
HexR binds to the promoters of the central metabolic operons of meningococcus, by 
targeting a DNA region overlapping putative regulatory sequences.  Our results indicate that 
HexR coordinates the central metabolism of meningococcus in response to the availability of 
glucose, and N. meningitidis strains lacking the hexR gene are also deficient in establishing 
successful bacteremia in a mouse model of infection.  
In parallel, RNAseq analysis of N. meningitidis cultured under standard or iron-limiting  
in vitro growth conditions allowed us to identify novel small non-coding RNAs (sRNAs) 
potentially involved in N. meningitidis regulatory networks. Manual curation of the RNAseq 
data generated a list of 51 sRNAs, 8 of which were validated by Northern blotting. Deletion 
of selected sRNAs caused attenuation of N. meningitidis infection in a murine model, leading 
to the identification of the first sRNAs influencing meningococcal bacteraemia. Furthermore, 
we describe the identification and initial characterization of a novel sRNA unique to 
meningococcus, closely associated to genes relevant for the intracellular survival of 
pathogenic Neisseriae.  
Taken together, our findings could help unravel the regulation of N. meningitidis adaptation 
to the host environment and its implications for pathogenesis. 
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2 Introduction 
2.1 Meningococcal disease 
Neisseria meningitidis is a strictly human pathogen responsible for meningitis and sepsis, 
two devastating diseases that can kill children and young adults within hours, despite the 
availability of effective antibiotics. The meningococcal disease was first discovered in 1887 
by Anton Weichselbaum, who described the meningococcal infection of the cerebrospinal 
fluid of a patient (1). The meningococcal disease occurs mainly as sporadic cases in 
industrialized countries, even if small regions suffer from epidemic outbreaks (e.g. New 
Zealand). On the contrary, it is largely epidemic in the so-called “meningitidis belt” in the 
sub-Saharan Africa. Studies performed in Europe (2) have demonstrated that carriage rates 
are very low in the first few years of life, but sharply rise during adolescence, peaking at 10–
35% in 20–24-year olds, then decreasing to less than 10% in older age groups (2, 3). The 
reported annual incidence of meningococcal disease varies from 0.5 to 10 per 100,000 
persons; however, during epidemics the incidence can rise above 1 per 1,000 (4, 5). The case 
fatality rate ranges from 5 to 15%, and approximately 11 to 19% of individuals surviving the 
disease often suffer from permanent sequelae, including neurodevelopmental deficits, 
hearing loss, seizures, ataxia, hemiplegia as well as amputation of limbs (6-10). What 
changes the colonization state of the organism into a disease state is not entirely clear. Most 
cases of meningococcal disease occur in otherwise healthy individuals without identified risk 
factors and for reasons not fully understood. However, certain biological, environmental and 
social factors have been associated with an increased risk of disease. Infants under 1 year of 
age, with a peak between 0 and 7 months, are the population at highest risk of infection due 
to their immature immune systems (6.33-7.08 cases per 100,000). A second peak in 
incidence is observed in adolescents and young adults (14-24 years; 0.75 cases per 100,000) 
(11). Microbial virulence factors, environmental conditions facilitating exposure and/or 
acquisition, impaired immune system, human genetic polymorphisms as well as naso- and 
oro-pharyngeal irritation caused by smoking and/or respiratory tract infection represent 
important factors for disease development (6, 12-17). Diagnosis of meningococcal disease 
can be challenging as its classic signs and symptoms, such as rash, fever, and headache are 
unspecific especially in the early course of the illness, and may be diagnosed as a more 
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benign infection. Due to the rapid progression of meningococcal disease, however, if 
appropriate treatment is delayed it can lead to death within 24 to 48 hours from the first onset 
of symptoms (7).  
 
2.2 Neisseria meningitidis: pathogen and pathogenesis 
2.2.1 The pathogen 
N. meningitidis is a β-proteobacterium, Gram-negative diplococcus (Figure 1 ). It is aerobic, 
non-motile, non-sporulating, usually encapsulated and piliated. It is surrounded by an outer 
membrane composed of lipids, outer membrane proteins (OMPs), and lipooligosaccharide 
(LOS), a peptidoglycan layer and an inner membrane. Some meningococcal strains have a 
polysaccharide capsule attached to their outer membrane, and pathogenic strains are almost 
always encapsulated. The invasive potential of non-encapsulated disease isolates has recently 
been reported (18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Immuno-gold labelling and transmission electron microscopy of Neisseria meningitidis. Analysis of the strain 
was performed with antisera raised against the NadA adhesin. Scale bars: 200 nm (19).  
 
Traditionally, N. meningitidis strains are classified into serogroups according to the 
immunological reactivity of their capsules. With this method 13 different serogroups have 
been identified, although only the A, B, C, Y, X and W135 serogroups commonly cause 
invasive infections (Figure 1). Meningococci are further classified into serotype and 
serosubtype, based on antigenic differences in their major OMPs, PorA and PorB. The 
serological classification system, however, is limited due to high frequency of phase and 
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antigenic variation of outer-membrane structures, which has led to the development of DNA-
based approaches to characterize meningococcal strains. A genetic typing system based upon 
polymorphisms in seven housekeeping genes called Multilocus Sequence Typing (MLST) is 
now the golden standard for molecular typing and epidemiologic studies (20). Menigococci 
can thus be classified into lineages, termed clonal complexes. A clonal complex is a group of 
sequence types (STs) that share at least four of the seven loci in common with a central 
ancestral genotype (21). MLST technique has shown that the majority of disease associated 
isolates cluster into a minority of STs called hyperinvasive lineages (22). Why hyperinvasive 
meningococcal lineages are more pathogenic than others still remains unknown. 
 
 
 
 
Figure 1 Global distribution of invasive meningococcal serogroups. Graphical representation of serogroup-specific 
incidence in different geographical areas of the world (adapted from www.meningitisinfo.com). 
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2.2.2 Colonization and invasion 
N. meningitidis colonizes the upper respiratory tract in about 25% of the human population 
where it can live as commensal. This carrier state represents a successful commensal 
relationship between the host and the bacterium: it provides the only known reservoir for the 
human-adapted meningococcal infection and may also contribute to establishing host 
immunity (23). For largely unknown reasons, in a small subset of carriers meningococcus 
can invade the pharyngeal mucosal epithelium and disseminate into the bloodstream, causing 
septicemia. In a subset of cases, the bacteria can also cross the blood-brain barrier and infect 
the cerebrospinal fluid, causing meningitis.  
The pathogenesis of N. meningitidis is a complex multi-stage process (Figure 2). 
Meningococci may be acquired via respiratory droplets or saliva. Colonization of the upper 
respiratory mucosal surfaces by N. meningitidis is the first step in establishment of both the 
human carrier state and the invasive meningococcal disease (23). The first step in 
meningococcal colonization is the initial contact with nasopharyngeal epithelial cells 
mediated by Type IV pili, which may recognize the host receptor CD46 (24), then bacteria 
proceed to proliferate on the surface of human non-ciliated epithelial cells, forming small 
microcolonies at the site of initial attachment (23). After the initial colonization, there is a 
loss or down-regulation of the capsule, whose presence masks the outer membrane proteins 
by steric hindrance. This event can occur both via cell-contact induced repression (24) and 
by selection of low or no-capsule expressing bacteria due to phase variation (25). Close 
adherence of meningococci to host epithelial cells is then mediated by a variety of possibly 
redundant adhesins that were previously masked by the capsule. One trigger of 
meningococcal internalization is represented by interaction of the bacterial opacity proteins, 
Opa and Opc, with CD66/CEACAMs and integrins, respectively, on the surface of the 
epithelial cell (26). This results in the appearance of cortical plaques and the recruitment of 
factors leading to the formation and extension of epithelial cell pseudopodia within 
intracellular vacuoles (27). Once internalized in the epithelial cells, meningococcal survival 
depends on factors such as the IgA1 protease, which degrades lysosome-associated 
membrane proteins (28). Meningococci are capable of intracellular replication and this is due 
in part to the capacity of the organism to acquire iron through specialized transport systems, 
such as the hemoglobin binding receptor (HmbR), transferring binding protein (TbpAB) and 
lactoferrin binding protein (LbpAB) (29). This intracellular lifestyle gives the bacteria an 
9 
 
opportunity to evade the host immune response as well as to find new sources of nutrients, 
and is also a way to cross the epithelium and enter the bloodstream (23). In healthy 
individuals, bacteria that cross the mucosal epithelium are eliminated by serum bactericidal 
activity. However, in susceptible individuals meningococcus can occasionally cross the 
mucosal epithelial barrier, either through transcytosis or directly following damage to the 
monolayer integrity, or through phagocytes (30). Eventually, bacteria enter the bloodstream 
and have to evade the host defence mechanisms using strategies such as up-regulation of 
capsule expression, which can prevent antibody and complement deposition (31) and is both 
anti-opsonic and anti-phagocytic (30). Meningococcus can also recruit negative regulators of 
the complement cascade such as factor H, recruited by the factor H-binding protein (fHBP) 
(32), and complement regulators such as the C4-binding protein (C4bp) bound by PorA 
porins (33). Once inside the bloodstream, bacteria either multiply slowly, eventually passing 
across the brain vascular endothelium or the epithelium of the choroid plexus, resulting in 
infection of the meninges and the cerebrospinal fluid (34), or they undergo rapid 
multiplication in the bloodstream, resulting in clinical features of bacterial septicemia or 
meningococcemia (35).  
 
Figure 2 Stages in the pathogenesis of Neisseria meningitidis. Schematic representation of the steps of meningococcal 
colonization and infection (adapted from (30)). 
 
Meningococcal adaptation to the different host niches also occurs at the level of metabolism 
(36). Therefore, acquisition of nutrients that enable the bacterium to sustain growth and 
multiply is critical for the outcome of meningococcal disease. In fact, N. meningitidis is 
capable of adapting to different anatomical compartments of the host (37), where the 
10 
 
availability of key nutrients such as carbon sources is diverse. However, this bacterium 
requires a restricted variety of substrates such as glucose, lactate or pyruvate as sole carbon 
sources to initiate growth (38, 39). Glucose is one of the few carbon energy sources that N. 
meningitidis can use as sole energy source, and the preferred carbon substrate for growth of 
meningococcus in terms of biomass yield (40). Lactate has been shown to be essential for 
effective colonization and its acquisition has been implicated in the virulence of N. 
meningitidis (41). Studies of N. gonorrhoeae have shown that in media containing glucose, 
lactate stimulates metabolism and that this could affect pathogenicity (42). Nevertheless, 
glucose is the predominant carbon source in blood as well as in the cerebrospinal fluid (43), 
the two main niches of meningococcal infection. Moreover, about half of the genes essential 
for systemic infection encode enzymes involved in the metabolism and transport of nutrients 
(44). The ability to obtain and synthesize nutrients is therefore essential for meningococcus 
to survive in the different microenvironments that it encounters within the human host during 
the course of infection. 
Overall, the onset of meningococcal disease can be seen as a failed relationship between the 
meningococcus and the host. While factors that trigger meningococcal entrance in the 
bloodstream are not yet fully understood, they are likely dependent on both the host and 
pathogen sides and include impairing of the integrity of the human nasopharyngeal mucosa, 
the lack of a protective immune response and microbial factors influencing virulence (4, 5). 
 
2.2.3 Virulence factors  
The major virulence factor of N. meningitidis is the polysaccharide capsule (Figure 3), which 
plays a crucial role in meningococcal fitness, protecting the bacterium during airborne 
transmission between hosts (45), and facilitating colonization and virulence by protecting the 
meningococcus from desiccation and the host innate and adaptive immune effector 
mechanisms such as phagocytic killing, opsonization, antimicrobial peptides and 
complement-mediated bactericidal killing (46, 47). Like many other virulence factors its 
expression is phase variable (25) and capsule switching between one serogroup to another 
provides a selective advantage that allows the bacterium to evade opsonization or 
neutralization by natural or vaccine-induced protective anti-capsular antibodies (48). 
The lipo-polysaccharides of meningococcus are more accurately referred to as lipo-
oligosaccharide (LOS), because of the presence of repeating short saccharides instead of 
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long chain saccharides (Figure 3). LOS are the major constituent of the outer leaflet of the 
meningococcal outer membrane, responsible for the physical integrity and proper 
functioning of the membrane and required for resistance of N. meningitidis to complement 
(49). Phase and antigenic variations lead to different saccharide chains altering dramatically 
the antigenic properties of LOS and enabling individual meningococci to display a repertoire 
of multiple LOS structures simultaneously (50). 
 
Figure 3 Meningococcal cell compartments. Schematic representation of the different bacterial compartments and of the 
main components of the outer membrane, together with their known functions (adapted from (6)). 
 
Another group of major virulence factors involved in the interface between the bacterium 
and the host are the pili (Figure 3), long surface proteins that extend from the bacterial 
surface beyond the capsule (51, 52). The pilus is composed of identical subunits of pilin, 
expressed from the pilE locus. The pilE gene undergoes sequence variation due to 
homologous recombination with multiple non-expressed truncated pilS genes, resulting in 
different adhesive and immunogenic pili variants (53). Meningococcal pili belong to type IV 
pilus family, members of which undergo rapid extension and retraction. They represent the 
major contributor to adhesive property of the capsule and are involved in the initiation of the 
meningococcus-host cell interaction (54, 55). Together with the outer membrane adhesins, 
pili facilitate adhesion to host tissues having a crucial role in the initial establishment of 
encapsulated bacteria on mucosal surfaces, helping the penetration of the negatively charged 
barrier at the host-pathogen interface (56). In addition to adhesion, pili are involved in 
several other functions such as facilitating the uptake of foreign DNA from the extracellular 
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environment, a property that contributes to virulence by promoting genetic adaptability (57). 
Twitching motility generated by pilus retraction is important for passage through the 
mucosal layer, movement over epithelial surface and micro-colonies formation (58).  
N. meningitidis has evolved a number of other surface structures that mediate interaction 
with host cells. The two opacity proteins (Opa and Opc) are integral outer membrane 
proteins that mediate pathogen-host interaction (Figure 3), adhering to and invading of 
epithelial and endothelial cells (52). Numerous adhesins are generally expressed at low 
levels during in vitro growth but may be important during in vivo infections. Furthermore, 
several adhesins are subject to antigenic variation and/or phase variation, which allow 
bacteria to generate a broad and variable repertoire of surface structure that facilitates 
evasion of immune effectors mechanisms and adaptation to different niches (30). The 
neisserial adhesin A (NadA) was firstly identified during a bioinformatic analysis of the 
genome of a virulent N. meningitidis B strain looking for novel vaccine candidates (19). 
NadA is a surface-exposed member of the oligomeric coiled-coil adhesin family of bacterial 
trimeric autotransporter adhesins, such as YadA of Yersinia spp. (59) and HadA of 
Haemophilus influenzae biogroup aegyptius (60). It has been shown that NadA mediates 
adhesion to and invasion of human epithelial cells (61), suggesting a key role of NadA in 
bacterial adhesion to the naso- and oro-pharyngeal epithelia during meningococcal 
colonization of the human upper respiratory tract. NadA is a risk factor for the development 
of meningococcal disease, as it is present in 50% of the disease-associated strains and 
overrepresented, almost 100%, in hypervirulent meningococcal lineages (62, 63). Several 
other minor adhesins belong to the family of autotransporter adhesin. Among them, 
Neisseria Hia homologue A (NhhA), mediates low levels of adhesion to epithelial cells and 
to extracellular matrix components (64). The adhesion penetration protein (App), an 
autotransporter protein with a highly conserved aminoacid sequence, has been shown to 
mediate bacterial interaction to epithelial cells during the early stages of colonization. At 
later stages, App autocleavage may allow bacterial detachment, therefore facilitating 
bacterial spread (65). Meningococcal serine protease A (MspA) is homologous to App and 
may also be cleaved and secreted (66). The multiple adhesin family (Maf) is a family of 
glycolipid adhesins, characterised first in gonococci, which may play a role in Opa-
independent cell invasion (67).  
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PorA and PorB are the most abundant proteins present in the meningococcal outer membrane 
(Figure 3). These antigens comprise regions of relatively conserved sequence, which are 
predicted to form the beta-barrel structure of the proteins, interspersed with more variable 
regions, which form the putative surface-exposed loops. The monomers associate in trimers 
creating pores for the passage of small hydrophilic solutes necessary for bacterial 
metabolism. While not considered adhesins, they interact with numerous human cell types 
and proteins (68). PorA elicits a protective immune response in humans (69), while the role 
of PorB in stimulating immune protection is less clear, being immunogenic but poorly 
accessible for antibodies (70). 
The ability to escape the elaborate machinery of the human immune system is a key 
determinant in the virulence of human pathogens. Many factors contribute to the virulence of 
N. meningitidis, involving mechanism to face antimicrobial peptides, reactive nitrogen and 
oxygen species, complement-mediated killing and, ultimately, the humoral and cellular 
components of the immune system. Efflux pump have been shown to have a critical 
contribution to antimicrobial peptide resistance (71). Enzymes such as catalases (Kat), 
superoxide dismutase (SodB and SodC), nitrite reductase (AniA) and nitric oxide reductase 
(NorB) neutralize the toxic effects of reactive oxygen and nitrogen species generated by 
neutrophilis and macrophages (72-74). Also the complement system, an essential component 
of the innate immune response, plays a significant role in defence against meningococcal 
infection, as indicated by the increased susceptibility to N. meningitidis infections of patients 
with complement deficiencies (75). The complement system consists of a well-balanced 
network of circulating and cell surface-bound proteins that act as substrates, enzymes or 
modulators of a hierarchical series of extracellular proteolytic cascades. The complement 
activation is initiated by the classical (CP) or the lectin (LP) pathways and is amplified by 
the alternative pathway (AP). All of these pathways converge at the level of the C3 complex, 
leading to cleavage of C3 to C3b by C3 convertases. Deposition of C3b on the surface of an 
invading pathogen results
 
in its elimination through phagocytosis or lysis following assembly
 
of the membrane attack complex (MAC). N. meningitidis uses a variety of mechanisms to 
survive to the bactericidal action of the complement system, involving its capsule, LOS and 
other factors (47). One such factor is fHBP, a surface-exposed lipoprotein which binds 
human factor H (fH), the main inhibitor of the complement AP (76). Sequestering fH allows 
meningococci to use this down-regulator to limit complement activation on their surface. In 
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addition, the Neisserial Heparin-Binding Antigen (NHBA) has been described to bind 
heparin, which may increase bacterial serum resistance due to the potential interactions of 
heparin with fH (77). 
 
2.3 Meningococcal vaccines  
Meningococcal disease progresses rapidly and in its early stages it is easily misdiagnosed (6, 
7), making vaccination the best public health option worldwide and the most effective way to 
prevent outbreaks. No broadly protective vaccine is currently available to provide protection 
against all serogroups of N. meningitidis. Capsular polysaccharides have been successfully 
used as antigens to produce polysaccharide and glycoconjugate vaccines against four of the 
five disease-associated serogroups A, C, W-135 and Y. Quadrivalent vaccines against 
serogroups A, C, W-135 and Y include the conjugate vaccines Menactra (Sanofi Pasteur) 
and Menveo (Novartis), and the polysaccharide vaccine Menomune (Sanofi Pasteur) and 
Mencevax (GlaxoSmithKline) (78). A vaccine called MenAfriVac has been developed 
through a program called the Meningitis Vaccine Project to prevent meningitis group A 
infections in the African ‘meningitidis belt’ (79). 
In contrast, the group B capsule polysaccharide is not suitable as vaccine antigen because it 
consists of a homolinear polymer of α(2→8)N-acetyl neuraminic acid, also known as 
polysialic acid, which is structurally similarity to the sialic acid found in human neural tissue 
(80, 81). Consequently, it is a poor immunogen in humans and may elicit autoantibodies. 
Therefore, efforts to develop a group B vaccine focused mainly on non-capsular antigens, 
such as proteins or LOS. Detergent-extracted Outer Membrane Vesicles (dOMV) have been 
successfully used in Norway (82), Cuba (83), Chile (84) and New Zealand (85) to control 
epidemic disease outbreaks caused by specific MenB strains. 
A significant limitation of these vaccines is the breadth of coverage provided. The detergent 
treatment extracts the toxic LOS, but it also extracts other desirable antigens such as fHbp. 
Consequently, the porin protein PorA results to be the immuno-dominant antigen (86, 87). 
However, PorA is antigenically variable (88) so the immune response elicited is effective 
only against strains expressing the same PorA serosubtypes. 
The availability of whole genome sequences has contributed radically to change the 
approach to vaccine development, laying the fundaments for an in silico genome-based 
approach named Reverse Vaccinology (RV). RV aims to identify surface-exposed non-
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capsular antigens that are antigenically conserved among strains and that elicit a bactericidal 
serum response. This approach has led to the development of the recombinant protein 
vaccine 4CMenB (89, 90). The 4CMenB vaccine contains five genome-derived Neisseria 
antigens (GNA), which are formulated together. The vaccine formulation joins NadA (61, 
91), as well as two recombinant fusion proteins of fHbp (92, 93) and NHBA (77, 94) fused 
to the conserved meningococcal gene products GNA2091 and GNA1030, respectively. The 
vaccine formulation also includes detergent-extracted outer membrane vesicles (dOMVs) 
from the NZ98/254 strain (87). The 4CMenB vaccine was licensed as Bexsero in 2013, 
following its progression through clinical trials that have demonstrated its safety (95, 96) and 
its efficacy in inducing a protective immune response in infants, children, adolescents and 
adults against the majority of MenB strains (97, 98). 
Another licensed vaccine against meningococcal serogroup B is the recombinant protein-
based vaccine composed of equal amounts of lipidated fHbp variants from different 
subfamilies. This vaccine was licensed in October 2014 in the US for a target population of 
adolescents and young adults. In preclinical study, the bivalent vaccine elicited high 
bactericidal titers against different MenB strains, suggesting a good breadth of coverage 
(99). In a phase I trial, it was assessed that the vaccine was well tolerated in adults, 
adolescents and young children (99). However, it is not suitable for use in infants 
considering that it consists or purified lipoproteins known as TLR-2 agonists (100). In 
addition, the in vivo level of fHbp expression strongly affects the effectiveness of the 
bivalent vaccine.  
 
2.4 Genetics of N. meningitidis 
Genome sequences are available for a growing number of N. meningitidis strains. These data 
show that the meningococcal chromosome is between 2.0 and 2.2 megabases in size and 
contains about 2000 genes (101-104). The meningococcus shares about 90% nucleotide 
homology with either N. gonorrhoeae or the commensal N. lactamica. While approximately 
70% of the genome encodes for essential metabolic functions, about 10% of the genome is 
represented by mobile elements such as IS elements and prophage sequences (101), leading 
to DNA transfer between meningococci, gonococci, commensal spp. as well as other bacteria 
(105). Another evident characteristic of the neisserial genome is the high abundance of 
repetitive DNA sequences, polymorphic regions and genetic switch mechanisms (e.g. 
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slipped-strand mispairing) which lead to genetic instability, facilitating duplication or 
deletion of regions in the genome, as well as recombination (105). Except for the IHT-A1 
capsule locus, no specific core pathogenome has been identified (106), suggesting that 
virulence may be dependent on multiple redundant genes. The GC percentage is variable 
along the chromosome with an average of 51.63%, with defined regions of low GC content 
that likely have been acquired by relatively recent horizontal gene transfer events (107). 
These events are relatively common in N. meningitidis due to its natural transformation 
competence (108). For example, the acquisition of the capsule locus by horizontal gene 
transfer, possibly from Pasteurella multocida or P. hemolytica (104), appears to be a major 
event in the evolution of the pathogenicity of the meningococcus from an un-encapsulated 
ancestor (23). A central characteristic of the genome is its plasticity contributing to the non-
clonal behavior of meningococcus and its phenotypic diversity, which allow the bacteria to 
successfully adapt to the host.  
 
2.5 Gene regulation and adaptation to the host environment 
During infection, N. meningitidis can invade diverse sites within the human host, which 
represent different niches with respect to nutrient availability, environmental stress factors 
and competing microorganisms. Therefore meningococcus is subjected to constant selective 
pressures and its ability to rapidly adapt its metabolism and cellular composition to 
environmental changes is essential for its survival (109). Bacteria achieve adaptation to the 
environment either by changing their genotype (genome plasticity) or by transient alterations 
in gene expression. These two mechanisms are complementary and both lead to phenotypic 
variations.  
 
2.5.1 Genome plasticity 
The high natural competence of meningococci is a leading cause of horizontal gene transfer 
and therefore genome variability (110). In addition, the abundance of repetitive DNA 
sequences contributes to meningococcal genome plasticity. The most frequent repeat 
sequence element is the neisserial DNA uptake sequence (DUS). Nearly 2000 copies of this 
12-bp sequence involved in recognition and uptake of DNA from the environment (111) are 
found in the N. meningitidis genome. On the other hand, the 20-bp long dRS3 elements 
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promote both permanent genomic changes, such as insertions and chromosomal 
rearrangements (104) and recombination with exogenous DNA (103). Correia elements are 
mobile elements of 100-150 bp, which carry transcription initiation sequences as well as 
binding sites for DNA bending protein, suggesting that they may have a role in modulating 
the expression of nearby genes (112).  Finally, the meningococcal genome is also littered 
with insertion sequences (IS) and other repeat sequences whose function has not been 
completely determined yet, such as AT-rich repeats (101) and REP2 repeats (113). 
Another major source of genome plasticity is phase variation (PV), the adaptive process by 
which bacteria undergo frequent and reversible phenotypic changes resulting from genetic 
alterations in specific loci of their genomes. Short tandem sequence repeats are the basis for 
PV, which can occur during replication through slipped-strand mispairing, altering the unit 
number of these repeats. The presence of repeat units may cause a slippage during 
replication of either the synthesis strand, leading to addition events, or the template strand, 
leading to deletions in the newly synthesized filament (105). When occurring in the coding 
sequence of a gene or within its promoter region, PV can change the transcriptional and 
translational state of the gene by introducing frameshift mutations or changing the spacing 
between critical promoter elements. It has been proposed that in N. meningitidis over 100 
genes are potentially phase variable, altering mainly virulence-associated, surface-exposed 
molecules such as outer membrane proteins PorA, Opc, Opa, pili and adhesins, as well as 
LOS and capsule (105, 114-116). Meningococcal strains associated with disease have high 
frequency of PV, indicating that varying surface-exposed components provides substantial 
benefits during transmission between hosts (117). 
Distinct from phase variation, antigenic variation is a mechanism of immune evasion where 
bacteria express different moieties of functionally conserved molecules that are antigenically 
distinct within a clonal population. This process is distinct from phase variation, as only one 
variant is expressed at any given time, although the cell still contains the genetic information 
to produce a whole range of antigenic variants. In the pathogenic Neisseria species, antigenic 
variation occurs in several surface components, including type IV pili, LOS and Opa proteins 
(105). 
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2.5.2 Transcriptional regulators 
Survival under the rapidly changing conditions encountered within the host requires timely 
alterations in gene expression. Several environmental signals have been shown to have an 
impact on the N. meningitidis transcriptional regulation during host infection, such as iron 
(118, 119), zinc (120), nitric oxide (121) human saliva (122) and human blood (123, 124). At 
the transcriptional level, these alterations could be controlled by global factors, for example 
through changes in associations between different alternative sigma factors and core RNA 
polymerase, which reprogram the specificity of promoter recognition by the enzyme to allow 
expression of entirely new sets of target genes (125). In addition, different transcriptional 
regulators activated by various stresses can regulate the transcription of many genes 
important for survival and virulence. Although extensive transcriptional regulation is 
expected to accompany the infection process of N. meningitidis, only 36 putative 
transcriptional regulators are encoded by the meningococcal genome. This number is 
especially striking if compared to Escherichia coli, which harbors more than 200 
transcriptional regulators. This striking limitation for transcriptional regulation is possibly 
related to the restricted ecological niches of the Neisseriaceae (126). Only 5 of the predicted 
regulators have been characterized so far, and the regulons of 4 have been dissected in detail. 
Bacterial pathogenesis and survival are dependent on the ability to acquire iron (127), which 
is limiting during human infection being sequestrated by host iron-binding proteins. 
Although N. meningitidis does not produce siderophores for iron acquisition, it possesses 
outer membrane receptors that have been postulated to scavenge the iron-loaded 
siderophores secreted by other bacteria colonizing the nasopharyngeal tract (128) such as the 
hemoglobin binding receptor (HmbR), transferring binding protein (TbpAB) and lactoferrin 
binding protein (LbpAB) (29). However, since iron overload results in toxicity for the 
bacterium, meningococcus tightly regulates iron uptake by the ferric uptake regulator Fur 
(129). The Fur protein senses the intracellular iron concentration and binds to and represses 
iron uptake genes using ferrous iron as a co-repressor (118, 119, 130). Fur has been also 
reported to act positively in the expression of certain genes. The regulon of Fur comprises 
more than 200 genes (131) regulated either directly or by an indirect mechanism which 
involves a Fur-repressed small regulatory RNA named NrrF (132, 133). 
During colonization and infection, N. meningitidis is also exposed to highly divergent partial 
pressures of oxygen (72). The fumarate and nitrate reductase regulator protein (FNR) is a 
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transcriptional activator that enables meningococci to survive under oxygen limitation by 
inducing sugar fermentation and denitrification pathways, utilizing nitrite and nitric oxide as 
electron acceptors (134, 135). Under oxygen limitation, FNR binds to DNA and activates 
target genes as a dimer containing a [4Fe-4S] cluster. This cluster dissociates in the presence 
of oxygen, destabilizing the dimer, with loss of FNR activity (135, 136). Interestingly, the 
mediator of complement evasion fHBP has been shown to be positively regulated by oxygen 
limitation through a FNR dedicated promoter (137).  
N. meningitidis is often exposed to the gaseous free-radical nitric oxide (NO), generated both 
internally by its own metabolism and externally by the human host tissue, which is rich in 
macrophages, a potent source of NO during infection (138). The nitric oxide sensitive 
repressor (NsrR) is the major NO-responsive transcriptional regulator, repressing a small 
regulon of 4 genes.  As NO concentration increases, NsrR is specifically inactivated through 
the alteration of its iron-sulfur cluster, thus leading to up-regulation of denitrifying genes 
(121, 139). Another regulator potentially relevant to the infection process is the Neisserial 
adhesin Regulator (NadR), a MarR-like protein demonstrated to regulate expression of both 
the phase-variable meningococcal adhesin NadA (116, 140, 141) and the MafA1 and MafA2 
adhesins, shown to adhere to glycolipid receptors on human cells (142, 143). These genes are 
affected by NadR in opposing ways, depending on their specific promoter architectures 
(122). As typical of MarR-like proteins, a small molecule ligand, the 4-hydroxyphenylacetic 
acid (4HPA) catabolite of aromatic amino acids found in human saliva (144), acts as signal 
to alter the DNA binding activity of NadR in vivo, leading to repression or activation of its 
target genes (122, 145). Other transcriptional regulators of N. meningitidis include the LysR-
type regulator CrgA, that is upregulated upon contact with human epithelial cells and acts as 
a repressor of its own transcription and type IV pili subunits (146, 147); AsnC is a global 
regulator that controls the response to poor nutrient conditions by binding to leucine and 
methionine, two amino acids representing general nutrient abundance (148); the Zinc uptake 
regulator (Zur) is a Fur-like regulator that responds specifically to zinc and controls zinc 
uptake by regulating a TonB-dependent receptor that allows high affinity zinc acquisition 
(149, 150). 
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2.5.3 Small regulatory RNAs  
Small non coding RNAs (sRNAs) are regulatory elements whose essential role is well-
established in all organisms (151). In pathogenic bacteria, regulatory sRNAs are a 
heterogeneous group of transcripts, which modulate a wide range of physiological processes 
through different mechanisms (152, 153). These regulators often function as coordinators of 
adaptation and/or virulence, integrating environmental signals and controlling target gene 
expression (154-156). sRNAs are commonly classified according to their mechanism of 
action within bacterial cells. Riboswitches are RNA sequences within the 5’-untranslated 
region (UTR) of the messenger RNAs (mRNAs) they regulate, that can adopt different 
conformations in response to environmental changes or the binding of metabolites (157). 
RNA thermometers are structured cis-regulatory elements that alter the efficiency of 
translational initiation in response to temperature (158, 159). The CRISPR (clustered 
regularly interspaced short palindromic repeats) RNAs contain short regions of homology to 
foreign DNA sequences and can interfere with bacteriophage infection, plasmid conjugation 
and natural transformation (160-162). In a recent publication, an archaeal CRISPR system 
has been reported to target both RNA and DNA molecules (163). Some sRNAs can bind 
proteins and alter their functions (164). Finally, the most extensively studied class are 
sRNAs modulating translation and stability of target mRNAs through direct base pairing. 
This class of regulatory RNAs can be further divided into two distinct broad classes: the cis-
acting antisense sRNAs, encoded from the strand of DNA opposite to their mRNA targets 
and having extensive complementarity to these (165), and the trans-acting sRNAs, acting on 
multiple distal targets with a limited complementarity (153). RNA base-pairing interactions 
are usually in the 5-UTR of the target mRNA and have been shown to alter mRNA structure 
ultimately leading to changes in translation efficiency and, as a consequence, mRNA 
stability (154, 164). However, sRNAs can also interact with coding regions, regulating their 
targets not by translational control but by accelerating decay of the sRNA-mRNA duplex 
through RNase E, often in concert with the RNA chaperone Hfq (166-169). The majority of 
the regulation by the known trans-encoded sRNAs is negative (155, 170): base pairing with 
the target mRNA usually leads to repression of protein levels through translational 
inhibition, mRNA degradation, or both (171-173). However, activation of gene expression 
by sRNAs has also been reported (174). In such cases, base pairing of the sRNA disrupt an 
inhibitory secondary structure which sequesters the ribosome binding site (155, 175, 176). In 
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addition to their function as post-transcriptional regulators, some sRNAs may also encode 
for protein functions, providing for a dual role within the cell (177).  
The role of many different sRNAs in pathogenic bacteria has been elucidated so far, and 
sRNAs have been found to be involved in a number of cellular mechanisms, from 
remodelling of the metabolism and regulation of homeostasis (178), to repression of outer 
membrane protein synthesis (179-183), to adaptation and resistance to stress (184-186), to 
virulence and pathogenesis (184, 187-190), as well as biofilm formation (191) and quorum 
sensing system regulation (184, 192). Interestingly, in recent years evidence of regulation of 
host transcripts by pathogen- or symbiont-encoded sRNAs had been arising (163, 193), 
indicating that sRNA-mediated regulation could extend outside the bacterial cell and play a 
role in cross-communication between invading bacteria and their host. 
Activity of trans-encoded base-pairing sRNAs in Gram-negative bacteria often depends on 
the hexameric RNA chaperone Hfq, a homologue of the Sm-like proteins involved in 
splicing and mRNA decay in eukaryotes (168, 170). The Hfq protein is conserved in a wide 
range of bacteria and ranges in length from 70 to 100 amino acids (194). In all cases, the Sm 
motif is located in the N-terminal region of the molecule. The C-terminal domain seems not 
to play a significant role in the major functions of Hfq. In fact, a C-terminal truncated form 
of the E. coli Hfq lacking the C-terminal amino acids can replace the intact E. coli Hfq (195). 
The main role of Hfq in assisting sRNA regulation is to promote sRNA-mRNA base pairing 
via multiple mechanisms: it increases the annealing rates of RNA molecules (196-198), 
stabilizes cognate sRNA-mRNA duplexes (199), promotes the structural remodelling of 
sRNA and target mRNAs (200), and increases the local concentration of both RNA species 
(201). The centrality of Hfq in assisting regulatory circuits involved in fitness and virulence 
is highlighted by the pleiotropic effects of Hfq-KO in many pathogens, whose phenotypes 
include increased sensitivity to host defence mechanisms and attenuation in animal models 
(133, 202-205). Hfq–independent post-transcriptional regulation by sRNAs has been shown 
to occur in Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis, even 
though Hfq is present in these organisms (206, 207).  
The role of sRNA-mediated regulation in N. meningitidis has been investigated only in the 
last decade. Even as more and more high-resolution transcriptomic analyses of pathogenic 
Neisseriae become available (208-211), only few sRNAs have been characterized to date in 
meningococcus or the closely related gonococcus, and are involved in a number of critical 
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pathogenic processes including regulation of gene expression, natural transformation and 
antigenic variation (133, 162, 212-214). The trans-acting sRNA NrrF is synthesized during 
iron starvation and is involved in controlling iron metabolism and maintaining homeostasis 
(132, 133, 215). AniS, another trans-acting sRNA, was identified by a microarray screening 
of differentially expressed transcripts between N. meningitidis wild type and ∆hfq mutant 
strains, is induced under anoxia and may be involved in down regulation of FNR-repressed 
genes (212). A third sRNA had been identified in N. meningitidis strain H44/76 by 
RNAsequencing of a mutant in which σE is highly expressed (209). This was subsequently 
clarified to be the tracrRNA of the Type II CRISPR/Cas system of meningococcus, which 
has been recently shown to limit natural transformation of the bacterium (162). In addition, 
RNA thermometers have been identified in the 5’-UTRs of three meningococcal genes that 
are essential for resistance against immune killing (213). Interestingly, another novel sRNA 
has been proposed to facilitate the formation of a G-quadruplex DNA structure involved in 
antigenic variation of the pilus in gonococcus (214).  
 
2.5.4 Identification of novel sRNAs  
Despite the critical regulatory roles they play in many bacterial processes, non-coding 
regulatory sRNAs have not been readily identified and annotated within available bacterial 
genome sequences. Because of this, experimental strategies paired with bioinformatics 
analyses have become increasingly important for sRNA discovery (216, 217). The first 
sRNAs were fortuitously discovered using genetic screens, or through radiolabeling of total 
RNA and subsequent isolation of short-length fractions from gels (218). It was only very 
recently that many new sRNAs have been identified and characterized in a wide range of 
bacterial species. This was mainly possible thanks to the increased availability of novel 
technologies such as computational predictions of sRNAs (219, 220), high density (tiling) 
microarrays (208) and high-throughput cDNA sequencing (RNAseq) that are used to study 
sRNAs at the genome-wide level (221, 222). These latter techniques not only allow the 
identification of novel sRNAs, but also the analysis of the whole transcriptome of bacteria 
under different growth conditions. Tiling arrays carry up to hundreds of thousands of DNA 
oligonucleotides systematically covering the sense and antisense strand of a genome, 
including the intergenic regions (IGRs) from which most known sRNAs are expressed (219). 
An important issue with this kind of technique, as well as with RNAseq, is choosing 
23 
 
physiologically significant conditions to assess expression of sRNAs. Genomic tiling arrays 
have been successfully used to study the transcriptome of Neisseria meningitidis (208), 
Listeria monocytogenes (223), Bacillus subtilis (224), Halobacterium salinarum (225) and 
Mycoplasma pneumoniae (226), as well as specific genomic features in Escherichia coli 
(227) and Caulobacter crescentus (228). However, array-based approaches require hundreds 
of thousands probes and are limited by background noise and cross hybridization, and 
therefore requires extensive normalization (229). On the other hand, the RNAseq approach 
directly determines the cDNA sequence. A population of RNA is converted to a library of 
cDNA fragments with appropriate adaptors attached to one or both ends. Each molecule is 
then sequenced at a high-throughput rate, generating extremely high numbers of short reads, 
which are subsequently mapped to the reference genome to assemble a transcriptome map. 
In principle, any high-throughput sequencing technology can be used for RNAseq, and the 
Illumina, SOLiD and Roche 454 Life Science systems have already been applied for this 
purpose in bacteria (210, 230-235). A transcriptome analysis at nucleotide resolution can be 
used to improve genome annotation by facilitating the discovery of new genes or transcripts, 
the correction of gene annotation, the detection of UTRs and transcription start sites and the 
determination of operon structure (229). Furthermore, whole-transcriptome analysis now 
allows the global interrogation of sRNA abundance and antisense RNAs by allowing 
detection of transcripts arising from non-coding regions. For example, Perkins et al. detected 
55 intergenic regions that are likely to encode new sRNAs in Salmonella Typhi Ty2 (236), 
and the number of known sRNAs in L. monocytogenes has been more than doubled by a 
tiling-array based study (223). Recently, high-density arrays together with a new 
bioinformatic tool named chipSAD revealed the presence of 91 differentially expressed 
putative sRNAs after incubation of N. meningitidis in whole human blood (208). RNAseq 
studies have become increasingly widespread in recent years, allowing the identification of 
more putative sRNAs in various bacterial species ranging from B. subtilis (237) to 
Helicobacter pylori (232) and the related Campylobacter jejuni (238), to Vibrio cholerae 
(191) L. monocytogenes (239) and N. gonorrhoeae (210). Interestingly, RNAseq also 
allowed for the exploration of the relationship between sRNAs and the Hfq protein by co-
immunoprecipitation  (231, 240, 241).  
In conclusion, the technical evolution of whole-transcriptome analyses during recent years 
made possible to study in detail, possibly down to single-nucleotide resolution, the 
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involvement of elements such as transcriptional regulators, sRNAs, riboswitches and cis-
antisense regulators in the physiology and pathogenicity of any prokaryote. 
 
2.6 Objective of the study 
The aim of this work is to investigate the N. meningitidis transcriptome and global regulation 
under infection-relevant conditions, both at the transcriptional and post-transcriptional level.  
Here we assess for the first time the effect of glucose on N. meningitidis at the transcriptional 
level. Following this, we identify and characterize a HexR-like transcriptional regulator 
implicated in the glucose-responsive regulation, and we show that this regulator has an 
impact on the fitness of N. meningitidis during infection.  
In order to identify novel post-transcriptional regulators in N. meningitidis, we perform 
curated RNAseq analysis of meningococci grown under in vitro conditions. From this 
approach we derive a list of 42 putative small non-coding RNAs potentially involved in N. 
meningitidis regulatory networks. Deletion analysis of selected candidates leads us to the 
identification of the first sRNAs influencing meningococcal bacteraemia. Furthermore, we 
describe the initial characterization of a novel sRNA unique to meningococcus, closely 
associated to genes relevant for the intracellular survival of pathogenic Neisseriae.  
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3 Results I 
3.1 Global analysis of Neisseria meningitidis expression in response to 
glucose  
In order to investigate the effect of glucose on global transcription in Neisseria meningitidis 
and its involvement in the regulation of metabolic and cellular processes, we compared the 
expression profiles of bacteria grown in the presence or absence of glucose to exponential 
growth phase using custom Agilent oligonucleotide microarrays (212). A gene was 
considered differentially expressed when it displayed more than two-fold induction or 
repression in the glucose samples compared to the reference samples (t-test p ≤ 0.05). The 
global gene expression could be grouped in 13 functional categories (Figure 5). Four 
categories are found over-represented: energy metabolism (30%), hypothetical proteins 
(26%), transport and binding proteins (11%) and cell envelope (9%).  
 
 
 
Figure 4 Graphical representation of genes differently expressed in presence of glucose. Genes are grouped in 
functional categories according to the classification of TIGRfams. Transcriptional regulators found differently expressed are 
highlighted. 
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Growth of N. meningitidis MC58 strain in the presence of glucose altered the expression of 
82 genes (3.8% of the MC58 genome). Among these, 49 and 33 genes were up- and down-
regulated, respectively (Figure 5A). Those contiguous genes present in the same orientation 
and that exhibit similar regulation have been grouped into likely operons. The majority of the 
genes found to respond to glucose belong to energy metabolism. We found genes belonging 
to the Entner-Doudoroff (ED) pathway (zwf, pgl, edd, eda), the pentose phosphate pathway 
(tal) and the catabolic branch of the Embden–Meyerhof–Parnas (EMP) pathway (pgi1, gapB, 
pykA) to be highly up-regulated. On the other hand, genes belonging to the anabolic branch 
of the EMP pathway (pgi2, gapA) were found to be down-regulated. The presence of glucose 
therefore up-regulates genes that encode functions leading to sugar catabolism, and down-
regulates genes whose products catalyze the inverse reactions, thus promoting the utilization 
of available sugar energy sources. We also observed down-regulation of all genes involved 
in the tricarboxylic acids cycle (aldA, prpB, prpC, lpdA3, sdhABCD, sucCD) as well as in 
acetate production (ackA2). Genes related to aminoacid metabolism and transport were also 
differentially expressed. The NADPH-specific glutamate dehydrogenase (gdhA) was found 
up-regulated, together with genes related to aminoacid metabolism (trpF, purF). On the 
other hand, the NADH-specific counterpart to gdhA (gluD) was found downregulated, as 
well as the proline importer protein (putP). Coherently with the availability of a highly 
energetic carbon source such as glucose, we also found the lactate importer protein (lctP) to 
be down-regulated, together with a gene encoding a putative uracil permease (NMB1048), 
possibly the first step in the pyrimidine salvage pathway. 
In addition to metabolic changes, we also observed genes related to meningococcal 
pathogenesis being induced by glucose (Figure 5A). For instance, nspA encoding the 
Neisseria surface protein A implicated in binding of factor H and therefore immune evasion, 
was up-regulated by glucose as well as the capsule gene NMB0067 (siaD). Furthermore, 
several surface exposed proteins with immunogenic properties and proposed as vaccine 
candidates such as NMB0390 and NMB1468 were up- and down-regulated in the presence 
of glucose, respectively. Genes coding for proteins involved in the contact and interaction 
with the host were also differentially expressed in presence of glucose. As an example, the 
loci NMB0375 and NMB0652 encoding for the mafA (multiple adhesion family A), were up-
regulated by glucose. Interestingly, also NMB1214 encoding for a hemagglutinin/hemolysin-
related protein (Hrp), an adhesin highly immunogenic (242) was up-regulated in presence of 
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glucose. Other factors related to the cell envelope were found down-regulated in presence of 
glucose, such as NMB1807 (ponA) encoding penicillin-binding protein 1 and NMB0342 
(ispA) encoding intracellular septation protein A. Interestingly, both these genes have been 
found down-regulated in the glucose-rich human blood (124). 
Taken together, our data indicate that glucose is not only involved in the regulation of gene 
expression related to metabolism, but it also impacts on other majors pathways that are 
important during N. meningitidis interaction with the host.  
In order to confirm the results obtained in the microarrays expression profiling, we selected a 
subset of eight genes with fold change values ranging from highly up-regulated to down-
regulated and performed real-time quantitative PCR (qRT-PCR) (Figure 5B). The results 
obtained are similar to the microarray data with a good coefficient of correlation (r
2
=0.82) 
(Figure 5C). 
 
3.2 NMB1389, a HexR transcriptional regulator 
Having mapped the transcriptomic profile of N. meningitidis in response to glucose, we 
moved to an in silico analysis looking for potential glucose-responsive regulators involved in 
this molecular mechanism. Analysis of the N. meningitidis strain MC58 genome identified 
two potential carbon-related transcriptional regulators that were also differentially expressed 
in response to glucose: NMB1711 (gdhR) was down-regulated by glucose and has been 
previously described to be involved in the regulation of glutamate transport (243), and 
NMB1389 was up-regulated in presence of glucose (Figure 5 and Figure 6). We also 
searched for potential orthologues of the cAMP receptor protein (Crp) and the catabolic 
repressor/activator protein (Cra) in the N. meningitidis genome, however orthologues of 
these major carbon-source responsive regulators were not found. 
The NMB1389 gene encodes for a HexR-like transcriptional regulator from the RpiR family, 
whose members are often involved in sugar catabolism regulation in proteobacteria. It 
contains two domains, a helix-turn-helix (HTH) binding domain at the N-terminal region and 
a Sugar Isomerase (SIS) domain at the C-terminal region, which is predicted to bind 
phosphosugars. The NMB1389 (hexR) nucleotide sequence is highly conserved among the 
available N. meningitidis  genome sequences and is present in several species of the 
Neisseria genus such as N. gonorrhoeae, N. lactamica, N. macacae, N. sicca, N. mucosa, N, 
flavescens and N. elongata. 
28 
 
 
Figure 5 Transcriptional profile of N. meningitidis MC58 in response to glucose. (A) The relative ratios of the 
microarray competitive hybridizations are shown for glucose-responsive expression (MC58 +Glc versus MC58 -Glc). 
Differentially expressed  genes are shown with fold change larger than 2-fold and p ≤ 0.05. ED, Entner-Doudoroff pathway; 
PP, pentose phosphate pathway; EMP, Embden–Meyerhof–Parnas pathway; TCA, tri-carboxylic acids. (B) Comparison of 
microarray (grey bars) and qRT-PCR (black bars) expression data for eight selected genes. (C) Correlation between 
microarray and qRT-PCR results for the eight genes shown in (B).  
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In order to assess the role of HexR in meningococcal carbon metabolism regulation, we 
generated a knockout ΔhexR strain and we performed a global transcriptional analysis of 
wild type MC58 strain and its isogenic ΔhexR mutant strain grown in modified Catlin 6 
medium (C6) or in C6 with 1% glucose (C6+Glc) until mid-logarithmic growth phase. 
Thirty-six genes were found to be differentially expressed in the ΔhexR strain compared to 
the wild type in at least one condition, with a fold change threshold of two-fold and t-test p ≤ 
0.05 (Table 1). Although only 27% of the total glucose-regulated genes in N. meningitidis 
are also controlled by HexR, this regulator controls the majority (60%) of the glucose-
regulated genes belonging to the functional category “energy metabolism”. Interestingly, all 
genes differently expressed in the ΔhexR mutant grown in presence of glucose were found 
up-regulated (with the exception of pgi1, that is in operon with hexR and therefore 
susceptible to polar effects of the deletion), suggesting that HexR represses a variety of 
genes in response to glucose (Table 1). On the other hand, in the absence of glucose within 
the growth medium, the lack of hexR induced both up- and down-regulation of its target 
genes. Finally, we could observe 13 genes regulated by HexR and found with a fold change 
below the threshold in the wild type strain grown in presence or in absence of glucose, 
therefore suggesting that their control by HexR is not glucose-mediated (Table 1).  
In order to validate the results obtained in the hexR microarray experiments, we selected six 
genes showing diverse fold change levels across the two experimental conditions (C6 in the 
presence or absence of glucose) and performed qRT-PCR on RNAs extracted from the 
ΔhexR and the WT strains under those conditions. Results show good agreement with the 
microarray data (Figure 6A). We also performed the same analysis comparing the ΔhexR 
strain to either the WT strain or the complemented c-hexR strain in which expression of 
HexR had been induced with 1 mM IPTG. We observed similar trends and expression levels 
for the selected genes in the ΔhexR strain, whether comparing it to the WT or the c-hexR 
strain (Figure 6B). Taken together, these results confirm that the expression of these genes is 
regulated by HexR. 
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Table 1 List of genes differentially expressed in the ΔhexR mutant strain in the absence or in the presence of glucose.  
 
aMicroarray results are average values from three separate experiments (p ≤ 0.05).
Gene ID Gene name Function Putative Operon fold change p fold change p fold change p
NMB1393 edd phosphogluconate dehydratase NMB1393-1394 52,2 3,1E-10 4,8 2,2E-06 9,7 4,0E-05
NMB1394 eda 4-hydroxy-2-oxoglutarate aldolase NMB1393-1394 45,9 4,6E-04 5,9 4,8E-02 7,4 3,2E-02
NMB1392 zwf glucose-6-phosphate 1-dehydrogenase NMB1392-1387 8,5 0,0E+00 3,1 0,0E+00 2,7 0,0E+00
NMB2159 gapB glyceraldehyde 3-phosphate dehydrogenase NMB2159 7,2 4,2E-10 1,8 2,0E-05 6,7 1,4E-07
NMB0089 pykA pyruvate kinase NMB0089-0088 6,6 1,4E-07 1,6 8,4E-04 3,1 2,5E-05
NMB1391 pgl 6-phosphogluconolactonase NMB1392-1387 6,2 5,6E-05 2,0 1,0E-02 2,5 3,0E-04
NMB1390 glk glucokinase NMB1392-1387 4,5 2,3E-03 1,4 4,0E-01 2,4 1,4E-02
NMB0351 tal transaldolase NMB0351-0349 4,0 3,3E-08 1,5 7,8E-04 2,3 4,6E-06
NMB0350 hypothetical protein NMB0351-0349 2,4 2,2E-02 1,4 4,7E-01 2,3 1,0E-02
NMB1624 nirV putative nitrite reductase NMB1623-1624 2,2 4,5E-02 -1,2 6,8E-01 2,0 1,7E-02
NMB0207 gapA glyceraldehyde 3-phosphate dehydrogenase NMB0207 1,9 1,9E-02 11,6 2,0E-05 -5,7 1,3E-03
NMB1476 gluD glutamate dehydrogenase, NAD-specific NMB1477-1476 1,2 3,9E-01 3,2 2,0E-04 -7,3 6,0E-07
NMB0429 hypothetical protein NMB0429-0434 1,1 6,7E-01 7,1 2,5E-06 -3,3 3,6E-13
NMB0334 pgi2 glucose-6-phosphate isomerase NMB0334-0336 1,1 6,2E-01 2,1 9,8E-04 -4,2 1,3E-08
NMB1968 aldA aldehyde dehydrogenase A NMB1968 -1,2 2,6E-01 3,2 8,2E-05 -5,6 4,5E-07
NMB0430 prpB 2-methylisocitrate lyase NMB0429-0434 -1,4 7,2E-02 6,1 7,8E-05 -3,7 1,1E-06
NMB0432 conserved hypothetical protein NMB0429-0434 -1,4 1,3E-01 4,0 5,5E-05 -2,8 3,6E-04
NMB0431 prpC methylcitrate synthase NMB0429-0434 -1,6 3,6E-02 7,0 7,5E-05 -4,5 1,2E-06
NMB0433 acnA aconitate hydratase NMB0429-0434 -1,7 2,5E-01 3,6 2,0E-02 -2,4 9,2E-02
NMB0435 ackA2 acetate kinase NMB0435 -2,6 3,1E-02 3,0 1,5E-02 -2,2 4,1E-03
NMB1048 hypothetical protein, putative integral membrane protein NMB1048 -2,9 4,5E-02 -1,5 4,2E-01 -16,9 9,5E-05
NMB0792 transporter, NadC family NMB0794-0792 2,2 2,0E-03 3,6 1,5E-06 -1,9 6,4E-02
NMB0791 ppiB peptidyl-prolyl cis-trans isomerase NMB0791-0790 1,5 4,1E-02 2,2 2,0E-03 1,1 5,1E-01
NMB0401 putA proline dehydrogenase NMB0401 1,1 6,2E-01 2,2 1,4E-04 -1,7 1,8E-02
NMB0434 prpF putative AcnD-accessory protein NMB0429-0434 -1,4 5,0E-01 2,4 1,3E-02 -1,8 1,0E-01
NMB1088 conserved hypothetical protein NMB1088 -2,0 1,0E-02 1,2 3,6E-01 -1,5 1,8E-03
NMB2095 putative adhesin complex protein NMB2095 -2,0 1,1E-03 -1,1 6,8E-01 -1,6 5,9E-03
NMB0866 hypothetical protein, putative periplasmic protein NMB0866-0864 -2,0 4,4E-02 1,2 5,1E-01 -1,2 5,3E-01
NMB0763 cysK cysteine synthase NMB0761-0763 -2,1 6,5E-03 -1,2 2,6E-01 -1,7 4,4E-02
NMB1154 cysD sulfate adenylyltransferase, subunit 2 NMB1158-1151 -2,2 1,2E-04 -1,3 1,2E-01 -1,2 4,8E-01
NMB1191 cysN sulfate adenylyltransferase, subunit 1 NMB1196-1189 -2,2 7,5E-07 -1,2 3,0E-01 -1,2 4,7E-01
NMB1189 cysI sulfite reductase hemoprotein, beta-component NMB1196-1189 -2,3 1,6E-08 -1,2 2,6E-01 -1,8 1,7E-05
NMB1151 cysI sulfite reductase hemoprotein, beta-component NMB1158-1151 -2,4 3,8E-08 -1,2 8,3E-02 -1,7 2,3E-05
NMB0865 hypothetical protein NMB0866-0864 -2,5 5,0E-03 1,1 6,7E-01 -1,9 6,4E-02
NMB1388 pgi1 glucose-6-phosphate isomerase NMB1392-1387 -1,9 2,5E-02 -3,9 4,4E-04 3,5 4,0E-04
NMB1389 hexR RpiR/YebK/YfhH family protein transcriptional regulator NMB1392-1387 -154,1 2,3E-09 -166,7 6,6E-12 2,5 1,7E-05
Transcriptome analysisa
 ΔhexR vs MC58 in C6  ΔhexR vs MC58 in C6+Glc MC58 C6+Glc vs.C6 
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Figure 6 Validation of the ΔhexR microarray data. (A) Comparison of microarray (grey bars) and qRT-PCR (black bars) 
expression data for six selected genes, under glucose-lacking (left) or glucose-replete (right) conditions. (B) Comparison of 
qRT-PCR expression levels for the same genes as in (A), in the ΔhexR strain versus the WT strain (grey bars) and in the 
ΔhexR strain versus the complemented strain (black bars). 
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3.2.1 HexR directly binds to edd and zwf promoter regions 
The meningococcal hexR gene co-localizes with genes of the central carbohydrate 
metabolism (Figure 8A). We first expressed HexR as a fusion protein to a N-terminal 
histidine tag, and purified it by nickel affinity chromatography. We obtained good purity of 
the His-HexR protein and stability across dialysis steps as assessed by SDS-PAGE (Figure 
8B). We then analyzed the binding of purified HexR to the promoter regions of the central 
carbon metabolism genes we had found differently expressed in the ΔhexR transcriptional 
analysis. DNase I footprinting experiments showed that HexR is able to bind the promoter 
regions of the two divergent operons that control central carbohydrate metabolism in N. 
meningitidis . Specifically, HexR is able to protect a region inside the promoter of zwf, as 
well as two regions inside the promoter of edd (Figure 8A and C). However, the affinity of 
HexR for the mapped sites seems to be different between the two promoters. In fact, we 
identified a higher affinity site in the zwf promoter overlapping a putative -10 box and 
transcriptional start site (protected at 100 nM HexR) as well as a similar affinity site in the -
35 box of the edd promoter (protected at 128 nM); on the other hand, higher concentrations 
of HexR were needed to protect the region overlapping the -10 box and the +1 site of the edd 
promoter (640 nM) (Figure 8C). 
 
3.2.2 In silico prediction of N. meningitidis HexR DNA-binding consensus sequence 
From DNase I footprinting analysis we were able to identify three HexR-binding sites. These 
three operators were used to define a HexR-binding consensus sequence with a 17-bp 
pseudopalindromic motif (KTGTANTWWWANTACAM) (Figure 8D). This consensus 
sequence resembles the in-silico predicted HexR binding motif for Betaproteobacteria in the 
RegPrecise database (245). We then used this motif to search in silico for similar HexR-
binding sites in the N. meningitidis MC58 genome and correlated the results with our 
transcriptome data (Table 1). We identified five HexR-regulated operons with a potential 
HexR-binding site overlapping their promoter region (Figure 8E). This is the case of the 
central carbon metabolism genes zwf and edd (part of the ED pathway), gapB and pykA (part 
of the glycolytic branch of the EMP pathway) and tal (part of the pentose phosphate 
pathway). 
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Figure 7 (cont.) HexR directly binds to the promoter regions of genes involved in the central carbon metabolism. (A) 
Genetic organization of hexR locus and sequence of zwf-edd intergenic region. Bent arrows indicate operon transcriptional 
start sites identified by RNA sequencing experiment (data not shown). Putative promoter sequences are underscored. Probes 
used for DNase I footprinting experiments are highlighted. Bars indicate regions protected against DNase I digestion by 
HexR. (B) SDS-PAGE analysis of fractions from nickel-affinity chromatography of the HexR recombinant protein. SOL, 
soluble fraction after sonication; INS, insoluble pellet after sonication; FT, flow-through; 1-10, washing step fractions; E1-
10 POOL, pooled eluates; POST1-4, pooled eluates after each dialysis step. (C) DNase I footprinting of HexR binding to 
zwf and edd promoter regions. (D) HexR-binding consensus sequence derived from mapped sites on zwf and edd promoters 
(WebLogo 3.2). (E) Sequences matching HexR-binding consensus found upstream of HexR-regulated operons (fuzznuc, 
EMBOSS). Brackets indicate predicted HexR-binding sequences overlapping putative promoter elements. 
 
 
3.2.3 HexR binding affinity is not altered by KDPG (2-keto-3-deoxy-6-
phosphogluconate) 
Since HexR mainly regulates gene expression encoding for the central carbon metabolism, it 
is reasonable to speculate that one or more of the intermediate products of carbon 
metabolism could be an effector for HexR action. Therefore we tested several carbon 
metabolic intermediates such as keto-deoxy-6-phosphogluconate (KDPG), glucose-6-
phosphate, fructose-1,6-diphosphate and 6-phosphogluconic acid as putative effectors for N. 
meningitidis HexR binding in vitro. However, we could not observe any difference on the 
HexR binding affinity to its cognate targets in the presence of any of these molecules (Figure 
9). On the other hand, in P. putida and S. oneidensis, KDPG was reported to dissociate HexR 
from the target DNA (244). When we compared protein sequences, N. meningitidis HexR 
shows 41% identity with its orthologue in P. putida and 40% with S. oneidensis (strain MR-
1), whereas P. putida and S. oneidensis proteins have higher reciprocal identity (58%) 
(Figure 9). This difference may explain why we did not observe an effect for KDPG on 
HexR DNA-binding affinity under the in-vitro conditions used. Differences in the 
phosphosugar-binding C-terminal region of the protein could imply that N. meningitidis  
HexR may use a different effector than other proteobacteria. 
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Figure 8 HexR binding to the promoter region of zwf is unaffected by addition of phosphosugars. (A) DNase I 
footprinting of HexR binding to zwf promoter region. Bars indicate regions protected against DNase I digestion by HexR. 
Increasing concentrations of HexR protein were incubated with radiolabeled DNA in the presence of 400 µM of the 
indicated phosphosugars, representing intermediates of the central carbon metabolism pathways. KDPG, 3-Deoxy-2-keto-6-
phosphogluconic acid; G6P, glucose 6-phosphate; FBP, fructose 1,6-diphosphate; 6-PGA, 6-phosphogluconic acid. (B) 
Increasing concentrations of KDPG were incubated with radiolabeled DNA in the presence of a binding concentration of 
HexR protein. 
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Figure 9 Comparison of HexR proteins in proteobacteria. Multiple alignment of HexR protein sequences (Clustal 
Omega). Common amino acids among the three protein sequences are shaded in grey. 
 
 
 
3.2.4 HexR deletion does not alter N. meningitidis resistance to oxidative stress 
The expression of nirV (NMB1624), encoding for a putative nitrite reductase, was found up-
regulated by glucose through HexR. Furthermore, upstream of NMB1624 it is located aniA 
(copper-containing nitrite reductase), and the aniA-nirV operon has been shown to be 
involved in N. meningitidis anaerobic respiration (121). Since anaerobic respiration also 
contributes to the ability of N. meningitidis to tolerate oxidative stress (121), we decided to 
test if the absence of HexR could affect sensitivity to oxidative stress agents, like H2O2 or 
paraquat. We performed disc-diffusion stress assays following the Kirby-Bauer method, but 
we did not observe any difference between the wild type and the ΔhexR mutant strains under 
the conditions used (data not shown).  
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3.2.5 HexR deletion impairs survival of N. meningitidis during infection in vivo 
In order to assess the viability of the ΔhexR mutant strain in vivo, a competitive index (CI) 
assay was performed in infant rats to determine the fitness of the mutant relative to the wild 
type strain. Growth curves in GC rich medium as well as in C6 medium with and without 
glucose showed no significant differences for the ΔhexR mutant as compared to the wild type 
strain (data not shown). The median CI observed for the challenged infant rats in the hexR 
experiment is larger than 1, indicating that more wild type bacteria (approximately 10-fold) 
survived in the animal model than ΔhexR mutant bacteria. As a comparison, the median CI 
for an unrelated KO strain that has no effect on meningococcal fitness in vivo is very close to 
1 (Figure 10). This suggests that the lack of HexR expression significantly affects the 
survival of N. meningitidis during in vivo infection. 
 
 
 
Figure 10 Deletion of hexR impairs survival during infection in vivo. Individual competitive indices (CI) from 
intraperitoneal challenge of infant rats with N. meningitidis WT and hexR-KO strains at a 1:1 ratio are shown. Circles 
indicate individual animals. Solid line indicates median, dashed line indicates CI=1. A CI >1 means the WT is more 
competitive than the mutant. Statistical significance was assessed with the Mann-Whitney test (ns, not significant). 
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4 Results II 
4.1 Deep sequencing analysis of N. meningitidis identifies novel putative 
small RNAs  
In order to explore the transcriptional landscape of N. meningitidis at nucleotide resolution, 
we performed RNAsequencing analysis (RNAseq) on total RNAs extracted from N. 
meningitidis MC58 strain cultured under standard or iron-limiting in vitro growth conditions, 
using a custom Illumina pipeline (ref. Materials and Methods).  
After read mapping and assembly, the resulting dataset was manually curated in search of 
novel small transcripts. As a proof of concept, we could detect the known iron-responsive 
regulatory small RNA (sRNA) NrrF (132) being more expressed under iron limitation 
(Figure 12A, left panel), as well as another meningococcal sRNA regulator, AniS (212), 
being repressed under iron limitation (Figure 12B, left panel). These findings are in line with 
previous reports and with Northern blot experiments performed under the same conditions as 
our RNAseq (Figure 12A-B, right panels). We could also detect the expected expression 
profiles of various housekeeping bacterial sRNAs, such as the 6S RNA known to regulate 
RNA polymerase activity (246) (Figure 12C) and the transfer-messenger RNA involved in 
the rescue of stalled ribosomes (247) (Figure 12D). Taken together, these findings 
highlighted the power of our RNAseq analysis in identifying sRNAs. 
In curating our dataset, we selected areas of transcription longer than 50 base pairs (bp) that 
did not fall entirely within annotated open reading frames (ORFs) or tRNA genes on the 
same strand. Then we looked for promoter-like elements in the vicinity of each putative 
transcriptional start site, and for sequences capable of rho-independent termination near the 
end of identified transcripts. We also annotated the presence of known neisserial repeat 
sequences within each area of transcription. In total, we found 51 non-ORF, non-tRNA 
associated transcripts expressed in the MC58 strain of N. meningitidis (Table 2). These 
include transcripts of known function such as the 4.5S signal recognition particle RNA 
(248), the RNase P ribozyme (249) and the tracrRNA of the minimal Type II CRISPR/cas 
system of N. meningitidis, which has been shown to limit natural transformation of the 
bacterium (162). We also found known meningococcal sRNAs within our analysis, such as 
the abovementioned NrrF and AniS (Table 2). Interestingly, we found two sRNAs (BNS1 
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and BNS2) reported to be induced upon exposure of N. meningitidis to human whole blood 
(208) to be also synthesized under standard in vitro conditions (Table 2).  
Overall, this analysis identified 42 previously unreported transcripts expressed by N. 
meningitidis during in vitro growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Examples of RNA sequencing profiles for known small RNAs. Read mapping (upper panel), schematic 
representation of locus (lower panel) and Northern blot (right panel) for the regulatory sRNAs NrrF (A) and AniS (B), as 
well as the two housekeeping sRNAs 6S (C) and tmRNA (D). GC, mid-log sample; Dip 1-2, dipyridyl-treated samples.  
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Table 2 List of sRNAs identified by manual curation of the RNA sequencing dataset. 
 
 
 
a : > and < indicate the forward and the reverse strand, respectively .       
b : genomic coordinate of the first nucleotide giving a signal peak in the RNA sequencing dataset (MC58 genome)  
c : genomic coordinate of the last nucleotide giving a signal peak in the RNA sequencing dataset (MC58 genome).  
d : Fagnocchi et al., PLoS One submitted  
        
No. UP ORF DOWN ORF Orientationa Signal startb Signal Endc Length (nt) Terminator Notes
Common to tiling 
microarray analysisd
1 0011 0012 <<< 9156 8896 260 Y Y
2 0018 0019 <>< 18388 18686 298 N NIME-associated
3 0019 0020 <>< 18958 19276 318 Y NIME-associated
4 0021 0022 <>< 19660 19730 70 N NIME-associated
5 0022 0023 <>< 21179 21281 102 N NIME-associated
6 0049 0050 <>< 51720 52011 291 Y NIME-associated
7 0049 0050 <>< 52504 52835 331 N NIME-associated
8 0064 0065 <>> 74158 74482 324 N long 5'UTR
9 0224 0225 ><< 233537 233291 246 Y
10 0225 0226 <>< 234513 234974 461 Y
11 0322 0323 >>< 333019 333143 124 Y
12 0444 0445 >>> 458754 458970 216 Y
13 0754 0755 ><> 783335 783130 205 Y
14 0837 0838 >>> 864414 864529 115 N long 5'UTR Y
15 0882 0883 ><> 903783 903587 196 N
16 0898 0899 >>> 918175 918349 174 Y Y
17 0899 0900 >>> 919118 919351 233 Y Y
18 0914 0915 <>< 928073 928413 340 N
19 0997 0998 <<> 1014714 1014620 94 Y = 4.5S RNA
20 0999 1000 ><> 1020376 1020304 72 N Y
21 1000 1001 ><< 1022632 1021864 768 Y Y
22 1015 1016 ><< 1031165 1030805 360 Y = tmRNA
23 1022 1023 <>< 1038476 1038565 89 Y
24 1039 1040 ><> 1054878 1054824 54 Y
25 1049 1050 ><< 1067603 1067433 170 N
26 1069 1070 <>> 1090231 1090427 196 N
27 1205 1205 <<< 1210463 1210346 117 Y = AniS Y
28 1205 1206 <>< 1210426 1210498 72 Y
29 1251 1252 <>< 1258764 1258851 87 Y
30 1400 1401 <>< 1431963 1432411 448 N Y
31 1410 1411 ><< 1439977 1439888 89 N Y
32 1563 1564 <>< 1624303 1624382 79 Y = BNS1 Y
33 1649 1650 <>< 1717408 1717469 61 Y
34 1649 1650 <>< 1717607 1717669 62 Y
35 1650 1651 <>> 1718351 1718539 188 N long 5'UTR Y
36 1752 1753 <>> 1834475 1834684 209 N long 5'UTR Y
37 1787 1788 ><< 1876028 1875800 228 N NIME-associated
38 1787 1788 ><< 1875788 1875559 229 N NIME-associated
39 1787 1788 ><< 1875507 1875299 208 Y NIME-associated
40 1826 1827 <>> 1919690 1919756 66 Y = tracrRNA (CRISPR) Y
41 1880 1881 ><> 1985617 1985247 370 N Y
42 1923 1924 ><< 2022033 2021848 185 Y Y
43 1941 1942 <<< 2038729 2038619 110 N Y
44 1969 1970 ><> 2064856 2064740 116 Y
45 1982 1983 >>> 2081647 2082159 512 Y NIME-associated
46 2057 2058 <<< 2179866 2179624 242 Y = 6S RNA
47 2062 2063 >>< 2185395 2185493 98 Y = BNS2 Y
48 2073 2074 >>< 2195867 2195996 129 Y = NrrF Y
49 2132 2133 <<< 2240181 2240094 87 Y
50 2137 2138 ><< 2251791 2251410 381 Y = RNase P
51 2149 2150 <<< 2260429 2260231 198 N
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4.1.1 Validation of novel meningococcal small RNAs 
In a parallel study to our RNAseq, we performed tiling microarray analysis of in vitro 
cultured meningococcus to assess differential expression of transcripts arising from 
intergenic regions (IGRs) under seven conditions mimicking physiologically relevant 
stresses (Fagnocchi et al., submitted). Interestingly, 18 out of the 51 putative sRNAs 
identified by RNAseq were also found in the tiling microarray dataset (Table 2), suggesting 
that these transcripts are being synthesized during in vitro growth, and further up-regulated 
under specific stress conditions. 
We selected 8 putative sRNAs for validation, comprising 2 BNS previously validated by 
RACE (208) as well as 6 putative new transcripts. From the tiling microarray dataset we 
derived the conditions that induced maximal expression of each of these sRNAs and 
validated their presence by Northern blot (Figure 13). We obtained positive signals for all of 
the candidate sRNAs analyzed, corresponding to small transcripts in the range of 100-400 
nucleotides (nt) in length (Figure 13, left panel). As expected from the microarray data, the 
signal from sRNA0837-0838 was detected only in RNA extracted from logarithmic phase, 
while the other signals from sRNA0898-0899, sRNA0899-0900, sRNA1400-1401 and BNS2 
were significantly induced in stationary phase (Figure 13, left panel). sRNA1880-1881 and 
sRNA1923-1924 instead showed similar expression levels both in logarithmic and in 
stationary phase samples. A signal for BNS1 was detected only in Northern blot performed 
on total RNA from C6 minimal medium supplemented with glucose (Figure 13, left panel), a 
condition in which it shows induction in the microarray results. All of the validated sRNAs 
appear to be short intergenic transcripts having their putative promoters, transcriptional start 
sites and putative terminator sequences located in the IGR between two flanking ORFs. The 
exception to this is sRNA0837-0838, which is detected as a specific transcript of about 100 
nt possibly arising from the processing of a longer primary transcript that encompasses also 
NMB0838 (Figure 13, right panel).  
Putative ORFs have been identified only within the sequence of validated sRNA0899-0900, 
raising the question whether this transcript may code for a small protein or peptide. 
However, no ribosomal binding site could be identified upstream of the start codon for this 
ORF, and no function could be inferred from the predicted amino acid sequence (data not 
shown). 
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Altogether, experimental validation by Northern blot confirmed the identification by 
RNAseq of 6 novel and 2 previously identified meningococcal sRNAs. 
 
4.1.2 Deletion of selected sRNAs impairs meningococcal fitness in vivo 
In order to assess the role of validated sRNAs in meningococcal fitness in vivo, we generated 
knockout mutants in N. meningitidis strain 2996 and performed a competitive index (CI) 
assay was performed in infant rats to determine the viability of each mutant relative to the 
wild-type strain. We successfully deleted six validated sRNAs, comprising the two BNS 
(Figure 14A). Growth curves in GC medium showed no significant differences for the 
sRNA-KO mutants as compared to the wild type strain (data not shown). The median CI 
observed for the challenged infant rats in 3 out of 6 sRNA-KO experiments (BNS1, 
sRNA0898-0899 and sRNA1400-1401) is significantly larger than 1, indicating that more 
wild type bacteria survived in the infant rat blood than sRNA-KO bacteria (Figure 14B). 
This suggests that lack of expression of these sRNAs affects in vivo survival of N. 
meningitidis in the bacteraemia model. The remaining 3 sRNA-KO strains (BNS2, 
sRNA0899-0900, sRNA1923-1934) exhibit CIs not significantly different from 1, indicating 
that lack of their expression is not sufficient to alter meningococcal fitness in vivo.  
 
 
44 
 
 
 
Figure 13 Experimental validation of novel meningococcal small RNAs. Northern blot analysis (left), read mapping 
(upper right) and schematic representation of locus (lower right) for newly discovered N. meningitidis MC58 sRNAs. GC, 
mid-log sample; Dip 1-2, dipyridyl-treated samples. Conditions of maximum sRNA expression used for Northern blot 
validation were derived from a parallel analysis of the MC58 strain using tiling microarrays (Fagnocchi et al., PLoS One 
submitted). 
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Figure 13 (continued) Experimental validation of novel meningococcal small RNAs. Northern blot analysis (left), read 
mapping (upper right) and schematic representation of locus (lower right) for newly discovered N. meningitidis MC58 
sRNAs. GC, mid-log sample; Dip 1-2, dipyridyl-treated samples. Conditions of maximum sRNA expression used for 
Northern blot validation were derived from a parallel analysis of the MC58 strain using tiling microarrays (Fagnocchi et al., 
PLoS One submitted). 
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Figure 14 Deletion of sRNAs impairs meningococcal fitness in vivo. (A) Northern blot validation of the indicated sRNAs 
KO strains. RNAs were extracted from N. meningitidis  WT and relative KO strains each grown in the condition of maximal 
sRNA expression (ref. Figure 13). (B) Competitive indices (CI) from intraperitoneal infection of infant rats with N. 
meningitidis WT and the indicated sRNA KO strains at a 1:1 ratio. Circles indicate individual animals. Solid line indicates 
median, dashed line indicates mean. A CI >1 means the WT is more competitive than the mutant. The numerosity of each 
group and the results of statistical analysis are shown above the graph (*, p ≤ 0.05; ns, not significant). 
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4.2 sRNA1880-1881 is a novel small RNA unique to meningococcus that 
closely associates with pathogen-specific genes 
In our RNAseq results, the novel sRNA1880-1881 appears as two peaks next to each other 
of approximately 160 nt in length, suggesting that the NMB1880-1881 IGR might actually 
harbor more than one sRNA transcript (Figure 15A). However, Northern blot validation of 
sRNA1880-1881 detected a single signal close to 400 nt in length (Figure 13). To elucidate 
the nature of the transcript arising from this IGR, we generated a knockout mutant of 
sRNA1880-1881 in the MC58 strain of N. meningitidis, and probed total RNAs from both 
the mutant and the wild type strain with two different probes, each specific for one of the 
peaks detected in the RNAseq. Our results show that both probes detect the same specific 
signal close to 400 nt, a length compatible with the 370 nt that a transcript spanning both 
peaks would cover according to RNAseq (Figure 15B). Sequence analysis of the validated 
sRNA1880-1881 shows that this sRNA has putative promoter elements in the vicinity of its 
transcriptional start site as defined by RNAseq, and its sequence harbors two long 
complementary GC-rich stretches that are predicted to form a highly stable structure (Figure 
15C). The operon surrounding sRNA1880-1881 is absent in commensal Neisseriae and 
horizontally acquired by pathogenic species (250) and has been shown to be associated with 
the intracellular survival of invading gonococci (251). Analysis of the conservation of the 
locus in available neisserial genomes showed that the sRNA sequence is not present in  
N. gonorrhoeae and is exclusive to N. meningitidis, and is often subject to duplication across 
meningococcal strains (Figure 16). Interestingly, duplication of sRNA1880-1881 is always 
associated with sequence changes upstream of the +1 site of the newly inserted sRNA copy 
(Figure 16). These changes disrupt the predicted sRNA promoter by altering the spacing 
between its -10 and -35 elements (Figure 15C), possibly affecting expression of the 
duplicated sRNA copy in these strains. The sRNA1880-1881 gene also shows sequence 
variability across meningococcal genomes, as short deletions of 12-55 bp in length that are 
not exclusively associated with duplication events (Figure 16). Interestingly, deletions 
always affect the region between the two complementary GC-rich stretches located at the 
opposite ends of the sRNA sequence (Figure 15C), raising the question whether conservation 
of structural elements may be relevant for the function of sRNA1880-1881. However, 
searches for sRNA1880-1881 against the Rfam database of RNA families (252) returned no 
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results (data not shown), indicating that this small transcript is not found in any other 
bacterium. 
 
 
Figure 15 Validation of sRNA1880-1881 and generation of sRNA KO strain. (A) Schematic representation of 
sRNA1880-1881 locus and its expression profile on RNAseq. White and grey arrows indicate ORFs and sRNAs, 
respectively. Putative promoters are indicated by a bent arrow. Approximate positions of probes used for Northern blot 
experiments are highlighted. (B) Northern blot for sRNA1880-1881 expression in N. meningitidis WT and sRNA KO 
strains, using probes mapping on different regions of the RNAseq signal area. (C) Sequence (left) and predicted structure 
(right) of sRNA1880-1881. Putative regulatory and structural elements are highlighted.  
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Figure 16 sRNA1880-1881 is unique to meningococcus and closely associated with pathogen-specific genes. Schematic 
representation of sRNA1880-1881 locus and its conservation across Neisseria species. White and grey arrows indicate 
ORFs and sRNAs, respectively. Putative promoters are indicated by a bent arrow. Deletions in the sRNA sequence and 
changes in the putative promoter sequences are highlighted. 
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When amplifying across the NMB1880-1881 IGR, multiple PCR bands could be observed 
arising from N. meningitidis MC58 genomic DNA (Figure 17A). This suggests that 
amplicons of different sizes are present within the DNA population, reflecting variability in 
the IGR structure. Sequencing of cloned PCR products from NMB1880-1881 IGR 
amplification confirmed the presence of a duplicated sRNA1880-1881 sequence in our 
MC58 strain (Figure 17B), including the changes in the promoter sequence that are specific 
to strains harboring duplications (Figure 16). These findings indicate that the sRNA-
encoding NMB1880-1881 IGR is a locus of high plasticity and subject to both in-strain and 
between-strain duplication events. 
Taking our results together, we identified and validated a unique meningococcal sRNA that 
is closely associated to pathogen-specific genes and is prone to genetic rearrangement. 
 
 
 
Figure 17 Evidence for in-strain duplication of sRNA1880-1881. (A) PCR amplification strategy for sRNA1880-1881 
locus. (B) Schematic representation of expected locus sequence based on MC58 genome data and experimental results for 
sequencing of main IGR PCR band obtained in (A). White and grey arrows indicate ORFs and sRNAs, respectively. 
Putative promoters are indicated by a bent arrow. Changes in the putative promoter sequences are highlighted. 
 
 
 
51 
 
4.2.1 sRNA1880-1881 is not part of a regulatory network under in vitro conditions 
To better understand the role of sRNA1880-1881 within the regulatory networks of 
meningococcus, we tested its expression by Northern blot on total RNAs from  
N. meningitidis exposed to different in vitro conditions mimicking physiologically relevant 
stresses, or from mutant strains lacking known regulators or factors involved in sRNA 
activity and stability. Our results indicate that sRNA1880-1881 is stably transcribed across 
all conditions tested, and shows little or no changes in expression compared to known 
regulated sRNAs such as NrrF (Figure 18A). Having already generated a knockout mutant of 
sRNA1880-1881 in the MC58 strain of N. meningitidis (Figure 15B and Figure 18B), we 
compared the expression profiles of the sRNA1880-1881 KO to the wild type strain using 
custom Agilent oligonucleotide microarrays (212). However, deletion of this sRNA did not 
impact global gene expression at either logarithmic or stationary phase of growth, apart from 
a polar effect of the resistance marker used in engineering the KO strain (Figure 18C).  
Taken together, these results indicate that during in vitro growth sRNA1880-1881 does not 
integrate into a global regulatory network, either upstream or downstream of itself. 
Therefore, we hypothesized that this sRNA may have functional interactions with the 
pathogen-specific operon it is closely associated with. 
 
 
Figure 18 sRNA1880-1881 is not part of a 
regulatory network under in vitro 
conditions. (A) Northern blot showing 
expression of sRNA1880-1881 compared to 
the known regulated sRNA NrrF. (B) 
Genetic makeup of the MC58 sRNA KO 
strain used for microarray experiments. (C) 
Representation of microarray results 
comparing MC58 WT and sRNA KO strains 
at logarithmic or stationary phase of growth 
(p ≤ 0.05). Red and green circles indicate the 
threshold used for calling genes up- and 
down-regulated, respectively. 
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4.2.2 Expression of sRNA1880-1881 limits transcription of neighboring genes in vitro.  
As the NMB1880-1881-1882 operon is not expressed in vitro according to our RNAseq 
(Figure 19A), any effect of the sRNA1880-1881 deletion on the surrounding genes is 
difficult to measure. To elucidate the relationship between the sRNA and its neighboring 
genes, we generated a set of isogenic mutants of N. meningitidis strain MC58 driving 
inducible expression of the operon surrounding the sRNA. All the mutants in our panel 
express the NMB1880-1881-1882 genes under the control of a lac-repressed Ptac promoter, 
and they differ only by the architecture of the NMB1880-1881 IGR. In addition to 
reconstructing the wild-type IGR (sRNA wt strain) and generating a complete deletion 
mutant of sRNA1880-1881 (sRNA null strain), we also introduced engineered copies of 
sRNA1880-1881, carrying multiple point mutations in the putative promoter (sRNA mutP 
strain) or in the GC-rich stretches (sRNA mutGC strain) which are predicted to disrupt 
transcription of the sRNA and its structural features, respectively (Figure 19B). We induced 
expression of the operon from the isogenic mutants and compared the level of steady-state 
RNA for each gene to the wild type MC58 strain by qRT-PCR. Interestingly, in the sRNA wt 
strain we observed operon and sRNA expression at a very similar level to that of MC58, 
confirming that our isogenic mutants are correctly reproducing the functional architecture of 
this region in meningococcus (Fig. 19C, first and second cluster). Changing the putative 
promoter sequence from the optimal consensus reduces sRNA transcription almost as 
dramatically as a complete deletion, as we observed in strains sRNA mutP and sRNA null, 
respectively (Figure 19C, third and fourth cluster). This result highlights the relevance of the 
identified promoter elements for sRNA expression. On the other hand, disrupting the GC-
rich structural features as in the sRNA mutGC strain does not seem to impact the steady-state 
level of sRNA1880-1881 in a significant way (Figure 19C, fifth cluster). Regarding 
NMB1880-1881-1882 expression, we observe that lack of transcription of the sRNA 
increases IPTG induction of the operon RNA (Figure 19C, third and fourth cluster), 
suggesting that active transcription of sRNA1880-1881 may limit operon expression, either 
by interfering with the transcription machinery on the opposite DNA strand or by modulating 
the steady-state level of the operon messenger RNA.  
Further studies will be needed to elucidate the molecular mechanisms governing the 
functional interaction of sRNA1880-1881 with its neighboring genes, and to identify the 
physiological relevance of this regulation for meningococcus. 
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Figure 19 Expression of sRNA1880-1881 limits transcription of neighboring genes in vitro. (A) Schematic 
representation of sRNA1880-1881 locus and its expression profile on RNAseq. Solid and striped arrows indicate ORFs and 
sRNA, respectively. (B) Schematic representation of MC58 isogenic mutants for inducible expression of the NMB1880-
1881-1882 operon. Squares indicate elements of the inducible Pind promoter system. Engineered mutations in the sRNA 
promoter and in the GC-rich sequence are highlighted. (C) qRT-PCR expression levels for sRNA1880-1881 and the 
surrounding genes in the same panel of strains as in (B), upon induction of the Pind promoter with 1 µM IPTG.  
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5 Discussion 
The ability of microorganisms to detect and respond to variable external conditions, such as 
environmental stress and carbon sources availability in different niches, requires a 
coordination of sensing mechanisms and regulatory circuits (253) and is often crucial for the 
adaptation of pathogenic bacteria to the host environment. 
In the first part of this work, we show the transcriptional profile of N. meningitidis in 
response to glucose, one of the main carbon sources that meningococcus encounters in its 
different niches of colonization. Glucose induces the differential expression of a high 
number of genes, and interestingly some of them are found to have the same trend of 
regulation in response to human blood (123), where glucose is abundant. In N. meningitidis, 
glucose is mainly metabolized through the Entner–Doudoroff (ED) pathway and to a lesser 
extent by the pentose phosphate (PP) pathway (254, 255), while the Embden-Meyerhof-
Parnas (EMP) pathway is not fully functional, because it lacks the phosphofructokinase gene 
(40). Similarly, in Pseudomonas putida the ED pathway synthesizes the major part of the 
pyruvate (67-87%) and the PP pathway accounts for the remaining part (256). Accordingly, 
in our microarray analysis we found genes driving glucose catabolism through these 
pathways (glk, zwf, edd, eda, pgl, pgi1, gapB, pykA) to be highly up-regulated by the 
presence of glucose (Figure 20). On the other hand, genes from the gluconeogenesis (pgi2, 
gapA) are down-regulated in presence of glucose (Figure 20). This can have physiologically 
relevant consequences since gapA was shown to play a role also in adhesion (257) and is 
controlled by the repressor NadR (122). Furthermore, also the acetate kinase ackA2, involved 
in acetate production from acetyl-coenzyme-A (acetyl-CoA), was down-regulated by glucose 
(Figure 20). Since the catabolism of glucose results in the accumulation of acetate, a 
feedback effect of acetate surplus could explain this observation. Similarly, other pathways 
that would be directly affected by an overabundance of acetyl-CoA are found repressed in 
presence of glucose, such as the tricarboxylic acid (TCA) cycle enzymes prpB, prpC, lpdA3, 
sdhABCD and sucCD (Figure 20). Indeed, growth on glucose has been reported to reduce the 
levels of TCA cycle enzymes also in gonococci (258, 259). Interestingly, the glucose-
repressed genes encoding for the TCA cycle enzymes are also repressed in the glucose-rich 
human blood (123, 124) and in a recent report, the TCA cycle prp operon has been suggested 
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to help N. meningitidis in colonization of the propionate-rich and glucose-poor oral cavity of 
adults (260). Also the NADH-specific glutamate dehydrogenase gludD was found repressed 
in presence of glucose as well as the putP-putA operon involved in glutamate degradation 
and proline utilization. This suggests an interconnection between the carbon catabolism and 
the nitrogen metabolism in response to carbon source availability. On the other hand, the 
NADPH-specific gdhA was up-regulated by glucose. High-level expression of gdhA is 
dependent on ammonia assimilation from the TCA cycle intermediate 2-oxoglutarate and 
may result in growth advantages when glucose concentration is higher than that of lactate 
(261), such as in human whole blood, where gdhA has been found upregulated (123). 
Overall, we observed that N. meningitidis response to glucose modulates a higher number of 
genes compared to its response to other environmental signals such as zinc (17 genes, (120)), 
lactate (23 genes, data not shown) or iron (83 genes, (118, 119)). Furthermore, 11 genes 
found differentially expressed in presence of glucose show a similar pattern of expression 
when N. meningitidis is exposed to lactate (data not shown), suggesting that these genes 
respond to the availability of a carbon source rather than to the type of sugar added. Most of 
these genes encode for hypothetical proteins, but also proteins related to cell envelope such 
as NMB0342 (ispA), NMB1729 (exbB) and NMB0543 (lctP).  
This work identified a RpiR-family HexR regulator controlling the central carbon 
metabolism of N. meningitidis in response to glucose (Figure 20). The number of genes 
differentially expressed in a ΔhexR strain of N. meningitidis is similar to what has beeen 
reported for other proteobacteria (262). In other species, members of this family can be 
repressors such as RpiR in Escherichia coli (263), transcriptional activators like the GlvR of 
B. subtilis that modulates maltose metabolism (264) or dual-purpose transcriptional factors 
like HexR in Pseudomonas putida (244), P. aeruginosa (265) and Shewanella oneidensis 
(262). The N. meningitidis HexR acts as a repressor by binding specific DNA sequences 
within the promoters of its target genes, albeit with different affinities. In our DNA-protein 
footprinting experiments, we identified a 100 nM HexR affinity site within the promoter of 
zwf as well as a similar affinity site (128 nM) in the edd promoter, while a second site within 
the edd promoter required 640 nM HexR for protection. Similar results were obtained in P. 
putida, where 100 nM - 3μM of HexR were necessary to bind to the operators within the zwf 
and edd/gap-1 promoter regions by DNA footprinting (244). Perhaps interestingly, when 
looking at the transcriptome data the fold change for edd containing two HexR operators is 
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almost double that for zwf, where only one operator was identified. Overall, our in vitro data 
agree with what has been reported for HexR in other proteobacteria species, where it directly 
regulates the transcription of central carbon metabolism encoding genes (262). This is the 
case of P. putida, where HexR binds to the promoter region of the zwf-1 gene and functions 
as a repressor (266) or in S. oneidensis, where HexR was shown to bind to DNA regions of 
several genes including the zwf-pgl-edd-eda operon (262). In other species, HexR glucose-
responsive binding to the promoters of its target genes has been shown to be mediated by the 
ED pathway metabolite KDPG. Since the N. meningitidis HexR protein is divergent from its 
homologs in P. putida and S. oneidensis, this could explain why we did not observe an effect 
for KDPG on HexR DNA-binding affinity under the in vitro conditions used. Nevertheless, 
the HexR-binding DNA consensus is very similar between N. meningitidis, P. putida and 
Shewanella spp. , and common HexR-responsive genes are found between these species 
(244). 
 
 
Figure 20 Model of glucose- and HexR-mediated regulation in N. meningitidis. Schematic representation of the main 
metabolic pathways affected by glucose availability. Genes significantly up- (red) and down-regulated (green) by glucose 
are shown. Genes subject to glucose-responsive HexR repression are highlighted. ED, Entner-Doudoroff pathway; PP, 
pentose phosphate pathway; EMP, Embden–Meyerhof–Parnas pathway; TCA, tri-carboxylic acids cycle. 
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In E. coli, expression of the enzymes in the ED pathway is essential for the colonization of 
the gastrointestinal tract (267), whereas in P. putida the ED pathway plays an important role 
for the generation of redox currency that is required to counteract oxidative stress (268). 
Similarly, our results indicate that a meningococcal strain lacking hexR shows reduced 
fitness during in vivo infection, indicating the importance of this transcriptional regulator not 
only in the metabolic adaptation but also in the survival of N. meningitidis within the host. It 
would be interesting to investigate during which steps of the infection, such as adhesion, 
colonization, and/or multiplication is HexR mostly expressed in vivo and therefore regulating 
its targets. 
It is interesting to note that although N. meningitidis inhabits different niches in the host 
(such as the nasopharynx, blood or meninges) where nutrient availability is very diverse, it 
uses a restrict range of carbon sources, does not have a complete EMP pathway for carbon 
metabolism and has no equivalent to known global carbon catabolite regulators. This means 
that meningococcus does not follow the same paradigm of carbon catabolite repression 
(CCR) as reported for Enterobacteria or gram-positive low G+C bacteria, and that HexR 
plays a major role in the biology of N. meningitidis by regulating its central carbon 
metabolism in response to environmental signals. However, we have also shown that not all 
glucose responsive genes are regulated through HexR, such as nspA, suggesting that other 
mechanisms either transcriptional or post-transcriptional could impact gene expression in 
response to glucose.  
In the second part of this work, we report the curated identification of novel non-coding 
transcripts in N. meningitidis. RNAseq experiments are the de facto golden standard for 
discovery of novel small non-coding RNAs (221, 269, 270). We chose to explore the 
transcriptome of meningococci grown either under standard in vitro conditions or under iron 
limitation. Iron-regulated genes of N. meningitidis are both relevant to the infection process 
(109) and well characterized in the literature (118, 119, 132), providing us with solid 
benchmarks against which to validate our analyses. The number of small intergenic 
transcripts identified by curation of our RNAseq data is in line with recent findings on in 
vitro cultured Neisseria (210). In another recent report, a notably larger number of candidate 
sRNAs has been reported in gonococcus (211), highlighting the stringency of the criteria 
applied to our RNAseq curation. We identified different classes of sRNA transcripts, the 
most numerous being intergenic sRNAs, but we also identified 4 particularly long (100-300 
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nt) 5’-untranslated regions (UTRs) of genes. These may have regulatory functions in cis as 
riboswitches or thermosensors (158, 271) or even act as independent sRNAs after processing 
of a primary longer transcript (272). Interestingly, we also identified 10 putative transcripts 
of diverse lengths (70-500 nt) arising from the NIME repeat regions of the meningococcal 
genome (101). In order to validate our candidates, we derived information from a microarray 
analysis of meningococcal sRNAs differentially expressed under diverse in vitro conditions 
(Fagnocchi et al., submitted). In this report, the stationary phase of growth represents the 
condition in which most differentially expressed intergenic transcripts were identified, 
comprising 68% and 76% of total up- and down-regulated putative sRNAs, respectively. 
Accordingly, in our Northern blot experiments we could confirm the identification of 5 novel 
and 1 previously reported meningococcal sRNAs being induced in stationary phase, 1 novel 
sRNA arising from the processing of a 5’-UTR being repressed in stationary phase, as well 
as 1 previously identified sRNA expressed in presence of glucose. It should be noted that 
while putative sRNAs were identified based on the RNAseq profile of a standard mid-
logarithmic in vitro growth, Northern blot experiments for 4 out of the 8 tested sRNAs did 
not detect any signal from log phase total RNA samples. Due to the large difference in 
sensitivity between the two techniques, even a high number of reads for a sRNA in the mid-
logarithmic RNAseq dataset does not necessarily correlate to a commensurate Northern blot 
signal, in particular when the level of expression in the condition of maximum induction (i.e. 
stationary phase) is many fold higher than in the reference condition.  
Our in vivo experiments using a murine model of bacteremia showed that knocking out three 
sRNAs (BNS1, sRNA0898-0899 and sRNA1400-1401) affects the in vivo survival of  
N. meningitidis. Interestingly, the knockout of BNS1 generated the lergest CI values, 
suggesting a relevant role for this sRNA on meningococcal survival during infection. A 
genome-wide screening of insertional mutants of N. meningitidis (44) identified 73 genes 
that are essential for bacteremia, comprising genes involved in the same processes in which 
BNS1 has been implicated through microarray experiments: energy metabolism and 
transport of metabolic molecules, amino acid biosynthesis and purine, pyrimidine, 
nucleosides and nucleotides biosynthesis (Fagnocchi et al., submitted). Taken together with 
the results of HexR deletion in the same model of bacteremia, this highlights the tight 
correlation between the carbon metabolism of N. meningitidis and its survival in the host 
environment during infection. Several studies describe the emergence of sRNAs as 
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regulators of metabolism, with several found to act at the interface of bacterial metabolism 
and virulence factor expression. For instance, the E. coli Spot42 sRNA selectively turns off 
the synthesis of enzymes required for galactose metabolism when a preferred carbon source 
is available (273) and synergizes with the global transcriptional regulator Crp to contribute to 
the overall efficiency of CCR (274). Since there is no evidence of CCR regulators in the  
N. meningitidis genome, this highlights the importance of other mechanisms for regulation of 
metabolism, such as the HexR and BNS1/GntR regulatory networks. Furthermore, although 
deletion of three more sRNAs (BNS2, sRNA0899-0900, sRNA1923-1934) does not alter 
meningococcal fitness in this model, we cannot exclude that they may be involved in 
functions related to meningococcal pathogenesis that are not assessed by the model used. 
In this study we also report the discovery and initial characterization of a novel sRNA unique 
to meningococcus, transcribed antisense to an operon silent in vitro. The sequence of 
sRNA1880-1881 harbors two long complementary GC-rich stretches and is highly 
susceptible to copy number variation (CNV) both between different N. meningitidis strains 
as well as within different clones of the same strain. Recently, another sRNA harboring a 
GC-rich sequence capable of forming a complex secondary structure has been implicated in 
the antigenic variation of the gonococcal pilus via a recombination-dependent mechanism 
(214). The gonococcal pilE sRNA and the novel sRNA1880-1881 share no similarities apart 
from the presence of one or more GC-rich sequences. However, since these sequences are 
highly conserved across meningococcal genomes even when other parts of sRNA1880-1881 
may differ, it would be interesting to investigate whether CNV of this sRNA depends on the 
formation of secondary structures similarly to what has been reported for N. gonorrhoeae, or 
meningococcus uses a different mechanism altogether.  
The sRNA locus includes two operons: the NMB1880-1881-1882 operon comprises two 
genes encoding a putative iron-uptake system and a short hypothetical protein, while the 
diverging NMB1878/1879 gene is a member of the AraC family of transcriptional regulators 
(275). The homologue of the NMB1882 gene in N. gonorrhoeae has been shown to associate 
with the intracellular survival of invading gonococci (251). On the other hand, the AraC-like 
regulator is a homologue of MpeR in N. gonorrhoeae, which has been shown to activate 
expression of genes involved in iron uptake and antibiotic resistance (276, 277). The 
meningococcal MpeR has been shown to bind to the divergent promoter region of 
NMB1880, however transcriptional profiling could not detect any gene differentially 
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expressed upon deletion or overexpression of MpeR (278). This strongly suggests that the 
meningococcal MpeR protein is not active in regulating gene expression under in vitro 
conditions. On the contrary, sRNA1880-1881 is stably expressed under all the in vitro 
conditions tested, including iron limitation and lack of the Fur iron-responsive regulator. 
Furthermore, the steady-state transcript level of sRNA1880-1881 is not affected by deletion 
of the hfq gene, indicating that Hfq is likely not involved in the stability and/or turnover of 
this sRNA (168). Transcriptome profiling indicates that sRNA1880-1881 is not affecting 
global gene expression in vitro, however expression of this sRNA limits IPTG-induced 
transcription of the NMB1880-1881-1882 operon on the opposite strand. This suggests that 
the sRNA may have a role in tightly controlling the expression of the neighboring genes it is 
closely associated to, under conditions that do not require their activity. Since this operon is 
required for intracellular survival of invasive Neisseriae (251), it is tempting to speculate 
that the lack of activity of the MpeR regulator and the stable expression of sRNA1880-1881 
observed under in vitro conditions may be reversed during invasion of cells in the host, 
possibly leading to activation of an intracellular iron scavenging system. Further experiments 
will be needed to elucidate during which steps of the infection, such as adhesion and/or 
invasion of epithelial cells, may expression of sRNA1880-1881 and its surrounding genes be 
regulated. 
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6 Materials and Methods 
6.1 Bacterial strains and culture conditions 
N. meningitidis strains (Table 3) were routinely cultured in GC-based (Difco) agar medium 
supplemented with Kellogg's supplement I (279). Liquid cultures were grown to mid-
logarithmic or stationary phase in GC-based medium with Kellogg’s supplement I or in 
Catlin 6 modified medium (C6) with/without the addition of 1% glucose (w/v) (280) at 37°C 
in a 5% CO2 atmosphere. Strains were stocked in GC medium with 15% glycerol and stored 
at −80°C. When required, erythromycin (5 μg/ml), chloramphenicol (5 μg/ml), kanamycin 
(100 μg/ml) and/or isopropylβ-D-1-thiogalactopyranoside (IPTG) (1 mM) were added to 
culture media at the indicated final concentrations. For RNA sampling under different stress 
conditions, N. meningitidis was exposed to stresses as follows: 1) iron limitation: mid-
logarithmic cultures in GC medium exposed for 5 min to 250 µM 2,2-dipyridyl (Sigma), 2) 
heat shock: mid-logarithmic GC cultures exposed for 10 min to 44°C in a water bath. 3) 
minimal medium: mid-logarithmic cultures grown in C6 minimal medium, 4) glucose 
availability: mid-logarithmic cultures in C6 medium with the addition of 1% glucose (w/v), 
5) stationary phase: RNA collected from cultures 3 hours past mid-logarithmic phase, 6) late 
stationary phase: RNA collected from cultures 6 hours past mid-logarithmic phase. 
Escherichia coli DH5α (281) and BL21 (DE3) strains (282) were grown in Luria-Bertani 
medium, and when required, ampicillin and/or IPTG were added to achieve a final 
concentration of 100 μg/ml and 1 mM, respectively. 
 
6.2 Construction of mutant and complementation strains 
DNA manipulations were carried out routinely as described for standard laboratory methods 
(283). In order to obtain a hexR mutant of the MC58 and 2996 strains by replacing it with a 
kanamycin cassette, the pGEMT-hexRKO::Kan plasmid was constructed. The downstream 
region of the hexR gene containing 176 bp of NMB1388 and 119 bp of the hexR gene was 
amplified by PCR with primers HexR1/HexR2 generating a XbaI/BamHI fragment (Table 
4). Then the upstream region of hexR containing 311 bp of NMB 1390 and 90 bp of the hexR 
gene was amplified by PCR with primers HexR3/HexR4 generating a BamHI/HindIII 
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fragment (Table 4). Both fragments were inserted into pGEMT vector (Promega), and a 
kanamycin cassette was inserted into the BamHI site, between the flanking regions, 
generating pGEMT-hexRKO::Kan (Table 3). The plasmid was then linearized and used for 
transformation to make a hexR knockout mutant by selection on kanamycin leading to the 
generation of MC58 ΔhexR and 2996 ΔhexR strains, respectively (Table 3). 
 For the complementation of the MC58 ΔhexR null mutant, the hexR gene under the control 
of the  Ptac promoter and the lacI repressor was re-inserted into the intergenic region between 
the converging open reading frames (ORFs) NMB1428 and NMB1429, by transforming with 
pComCmrPind-hexR (Table 3), a derivative plasmid of the pSLComCm
R
 (284), in which the 
hexR gene was amplified from the MC58 strain with the primers GG006/GG007 (Table 4) 
and cloned as a 849 bp NdeI/NsiI fragment downstream of the Ptac promoter. This plasmid 
was transformed into the MC58 ΔhexR strain and transformants were selected on 
chloramphenicol.  
To generate sRNA-KO mutant strains, the upstream and downstream flanking regions of 
each sRNA were amplified by PCR with specific primer pairs (Table 4). Then the respective 
upstream and downstream flanking regions were fused through self-priming PCR, amplified 
with external primer pairs and cloned as PCR products carrying a BamHI or XmaI restriction 
site between upstream and downstream flanking regions in the pGEMT (Promega) or 
pBluescript (Novagen) vector. The plasmids containing the sRNA flanking regions were 
digested with BamHI or XmaI and an erythromycin cassette  was inserted generating 
pGEMT- or pBluescript-sRNAKO plasmids (Table 3). Following linearization these 
plasmids were used to transform MC58 and 2996 strains, generating the corresponding 
ΔsRNA strains (Table 4).  
In order to construct MC58 isogenic mutants for inducible expression of the NMB1880-
1881-1882 operon, a KO mutant of the region of interest was generated. The pGEMT-
1880KO::Ery plasmid was constructed as follows: flanking regions comprising the 
NMB1878-1879 and NMB1881-1882 sequences were amplified from genomic DNA with 
oligos GG180/GG181 and GG186/GG188 respectively (Table 4), then fused through self-
priming PCR, amplified with external primer pairs and cloned as a PCR product carrying a 
BamHI restriction site between upstream and downstream flanking regions into pGEMT 
vector (Promega), generating pGEMT-FLA-1880 (Table 3); then an erythromycin cassette 
was inserted into the BamHI site, between the flanking regions, generating pGEMT-
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1880KO::Ery (Table 3). The plasmid was linearized and used for transformation to generate 
a MC58 1880KO knockout mutant (Table 3) by selection on erythromycin. To construct the 
isogenic complementation mutants, first the pCOM1880-Pind-null construct was generated. 
Flanking regions comprising the NMB1878-1879 and NMB1881-1882 sequences were 
amplified from genomic DNA with oligos GG180/GG185 and GG187/GG188 respectively 
(Table 4), while the NMB1880 gene was amplified with oligos GG189/GG190 (Table 4). 
The three PCR products were then cloned into pComCmrPind as XmaI/XbaI, NsiI/SpeI and 
NdeI/NsiI fragments respectively, generating pCOM1880-Pind-null (Table 3). In vitro 
synthesis (Life Technologies) produced plasmids pMK-sRNAwt, pMK-sRNAmutP and 
pMK-sRNAmutGC, each harboring one copy of sRNA1880-1881 with either the wild type 
sequence, or a sequence with mutations in the promoter elements or in the GC-rich stretches 
(Table 3). Subcloning of these sequences into pCOM1880-Pind-null as XhoI/NsiI fragments 
generated pCOM1880-Pind-sRNAwt, pCOM1880-Pind-sRNAmutP and pCOM1880-Pind-
sRNAmutGC respectively (Table 3). The four plasmid were linearized and used for 
transformation to generate the MC58 isogenic mutants of the same name (Table 3) by 
selection on chloramphenicol. All transformants were verified by PCR analysis for the 
correct insertion by a double homologous recombination event. 
 
6.3 RNA preparation 
Bacterial cultures were grown in liquid medium to an OD600 of 0.5-0.7 and then added to 
equal volume of frozen medium to bring the temperature immediately to 4ºC. Cells were 
harvested by centrifugation at 3400 g for 20 minutes. In preparation for transcriptome 
experiments, total RNA was isolated using the RNeasy Mini kit (Qiagen) following the 
manufacturer’s instructions. Total RNA was extracted from three independent bacterial 
cultures and 15 μg of each sample were pooled together. Three independent RNA pools were 
prepared for each condition tested.  
For Northern blot analysis of sRNA expression, total RNA was isolated using TRIzol 
reagent (Life Technologies) following the manufacturer’s instructions. Briefly, bacterial 
pellets were resuspended in 1 ml of TRIzol reagent and incubated at room temperature for 5 
minutes. Then the aqueous phase was extracted by adding 0.2 ml of chloroform (Sigma), 
thouroughly mixing, and centrifuging at 12000 x g for 15 minutes. Nucleic acids were then 
precipitated from the aqueous phase by adding 1 volume of 100% ethanol and 0.1 volumes 
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of 3 M sodium acetate (Sigma) (pH 5.2) and incubating 30 minutes on dry ice. After 
incubation, samples were centrifuged again at 12000 x g for 30 minutes, washed with 1 
volume of 70% ethanol in water (v/v), and dried at room temperature. Pellets containing 
nucleic acids were added of 80 µl of DEPC-treated water (Ambion) and left to resuspend 
overnight, then treated with 10 µl RQ1 DNase (Promega) for 1 hour at 37°C. The DNA-free 
RNA was then extracted with phenol:chloroform:isoamylalcohol (Sigma) and precipitated as 
above. Dried RNA pellets were left to resuspend overnight in DEPC-treated water, then 
stored at -80°C. 
 
6.4 Northern blot 
Northern blot analysis was carried out using the Northern-Max kit (Ambion) according to the 
manufacturer’s instructions. In brief, 3-5 µg of total DNA-free RNA were fractionated on 
1% agarose-formaldehyde gel and transferred onto an Hybond XL nylon membrane (GE 
Healthcare) through capillary blotting. Then 5 pmol of radioactively labeled primers (Table 
4) were used as probes. Hybridization was performed at 37°C overnight, low-stringency 
washes at room temperature. 
 
6.5 Microarray procedures, hybridization and analysis 
DNA microarray analysis was performed using an Agilent custom-designed oligonucleotide 
arrays. Briefly, cDNA probes were prepared from 5 μg of RNA pools and hybridized as 
described previously (212). Three hybridizations were performed using cDNA probes from 
three independent pools. Differentially expressed genes were assessed by grouping all log2 
ratios of the Cy5 and Cy3 values corresponding to each gene, within experimental replicas 
and spot replicas, and comparing them against the zero value by Student’s t test statistics 
(one tail). 
 
6.6 RNA sequencing 
Whole transcriptome pair-ended cDNA libraries were synthesized using the Ambion 
RNAseq Library Construction Kit (Life Technologies) from total RNAs extracted from  
N. meningitidis cultures grown to mid-logarithmic phase under standard in vitro conditions 
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or exposed to iron limitation. Libraries were sequenced with a HiSeq2000 platform 
(Illumina). Reads were mapped with bowtie 0.12.7 (285) on the Neisseria meningitidis 
MC58 reference genome NC_003112.2 (NCBI), then visualized on the Artemis genome 
browser (286). 
 
6.7 Quantitative real-time PCR (qRT-PCR ) experiments 
2 μg of total RNA treated with Tubo-free DNase (Ambion) was reverse transcribed using 
random hexamer primers and M-MLV reverse transcriptase (Promega) following the 
manufacturer’s instructions. Real-time quantitative RT-PCR was performed with triplicate 
biological samples in a 25 μl reaction mixture containing 80 ng of cDNA, 1X Brilliant II 
SYBR green quantitative PCR master mixture (Agilent) and 0.2 μM of gene-specific primers 
(Table 3). Amplification and detection of specific products were performed with an 
LightCycler 480 Real-Time PCR system  (Roche) using the following procedure: 95ºC for 
10min, followed by 40 cycles of 95ºC for 30 s, 55ºC for 1 min and 72ºC for 30 s then ending 
with a dissociation curve analysis. The 16S rRNA gene was used as the endogenous 
reference control and the relative transcript change was determined using the 2
-ΔΔCt
 relative 
quantification method (287). Student’s t-test was used to calculate statistical significance (p 
< 0.05). 
 
6.8 Expression and purification of recombinant HexR 
The hexR gene was amplified from the MC58 genome using primers GG012/GG013 (Table 
3) and cloned as a 843 bp fragment into pET15b(+) (Life Technologies) vector via the 
polymerase-incomplete primer extension (PIPE) enzyme-free cloning method (288), 
generating pET15b-HexR plasmid (Table 4). This plasmid was transformed into the E. coli 
BL21(DE3) strain and the expression of a recombinant HexR protein containing a N-
terminal histidine tag (His-tag), was induced by the addition of 1 mM IPTG and grown at 
25°C for 6 h, and the protein was purified by Ni-NTA (Qiagen) affinity chromatography 
under non-denaturing conditions according to the manufacturer’s instructions. In brief, 
IPTG-induced E. coli cultures from above were concentrated in Lysis Buffer (20 mM Tris, 
500 mM NaCl, 10 mM imidazole, chicken egg lysozyme 1 mg/ml), supplemented with 
Complete EDTA-Free Protease Inhibitor Cocktail (Roche) and incubated 30 min at 4°C. 
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Lysis was then performed by sonication, and cleared, filtered supernatants were applied to 
the column for nickel-affinity purification. After washing the Ni-NTA resin with 12.5 
volumes of Wash Buffer (20 mM Tris, 500 mM NaCl, 25 mM imidazole), the His-HexR 
protein was eluted with 2.5 volumes of Elution Buffer (20 mM Tris, 500 mM NaCl, 250 mM 
imidazole). Eluted fractions were collected and pooled together, and protein concentrations 
were determined by the Bradford colorimetric method (Bio-Rad). Pooled eluates were then 
dialyzed four times against 150 volumes of Storage Buffer (20 mM Tris-HCl pH 8.0, 100 
mM NaCl, 1 mM DTT, 10-50% glycerol) increasing the concentration of glycerol stepwise, 
up to 50% final glycerol. 
 
6.9 DNase I Footprinting 
The zwf and edd promoter regions were amplified with the primer pairs GG034/GG035 and 
GG036/GG037 respectively. The PCR products were purified and cloned into pGEMT 
vector (Promega) as 321 bp and 386 bp fragments generating pGEMT-Pzwf and pGEMT-Pedd 
respectively. Two pmol sample of each plasmid was end labeled by T4 polynucleotide 
kinase with [γ-32] ATP after digestion at either the XhoI or BamHI site introduced by PCR 
with the oligos above. Following a second digestion with either BamHI or XhoI, the labeled 
probes were purified by polyacrylamide gel electrophoresis (PAGE) as described previously 
(116). DNA-protein binding reactions were carried out for 15min at room temperature in 
footprinting buffer (20 mM Tris HCl pH 8, 50 mM KCl, 5 mM MgCl2, 1 mM CaCl2, 1 mM 
DTT, 0.05% Nonidet-40) containing 60 fmol of labeled probe, 100 ng of salmon sperm DNA 
and a range of HexR concentrations as indicated in the figures. Samples were then treated 
with 0.3 U of DNase I (Roche) for 2 min at room temperature. DNase I digestion were 
stopped and samples purified loaded and run on a 8 M urea 6% polyacrylamide gel as 
described previously (289). Where indicated, reactions were supplemented with the 
phosphosugars 3-Deoxy-2-keto-6-phosphogluconic acid (Sigma), glucose 6-phosphate 
(Sigma), fructose 1,6-diphosphate (Sigma) or 6-phosphogluconic acid (Sigma) at 
concentrations of 400 – 4000 µM prior to addition of the labeled probe. A G+A sequence 
reaction (290) was performed for each probe and run in parallel to the footprinting reactions.  
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6.10 Bioinformatic analysis of the HexR binding site 
The HexR-binding consensus sequence was derived from aligning the three 17-bp sites 
mapped on the zwf and edd promoters by DNase I footprinting. The sequence of each 
intergenic region from the MC58 strain genome was extracted and scanned in silico for the 
presence of HexR-binding motifs via the EMBOSS fuzznuc algorithm (Alan Bleasby, 2000). 
Structure of operons and putative transcriptional start sites were determined based on the 
RNA sequencing experiment.  
 
6.11 Bioinformatic analyses of small RNAs 
Open reading frames were predicted by submitting the sRNA sequence to the NCBI ORF 
Finder. Results were then manually curated by analyzing the sequence upstream of each 
putative ORF looking for matches to the consensus Shine-Dalgarno ribosomal binding 
sequence (AGGAGGU) around 6 bp upstream of the predicted starting codon. ORFs lacking 
a good RBS or predicted to be shorter than 10 aminoacids were discarded from the analysis. 
RNA secondary structures were predicted with the mfold web server (291). Conservation 
analysis of sRNA1880-1881 was performed by aligning the NMB1877-NMB1882 genomic 
region from MC58 strain with the homologous regions in available neisserial genomes. 
Results were visualized and interpreted by means of Geneious software (BioMatters). 
 
6.12 Amplification and sequencing of NMB1880-1881 intergenic region 
The intergenic region harboring sRNA1880-1881 was amplified from the MC58 strain with 
the primers GG103/GG106 (Table 4). Multiple products arising from Taq PCR amplification 
were separated on agarose gel, purified and TA-cloned into the pGEM-T vector (Promega).  
Clones positive for the presence of an insert in the pGEM-T multiple cloning site were 
sequenced with different oligos spanning across the NMB1880-1881 IGR (Table 4) and the 
resulting reads were assembled to reconstruct the IGR sequence of our MC58 clone. 
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6.13 Disc diffusion viability assays 
Sensitivity of N. meningitidis strains to different stress agents was assayed by means of a 
modified Kirby-Bauer disc diffusion method (292). In brief, approximately 5 x 10
8
 bacteria 
from mid-logarithmic phase cultures were inoculated in 6 ml of GC soft agar (8 g/l) and 
poured onto square GC plates (25 ml). After 30 min, up to five Whatman paper discs (6-mm 
diameter; GE Healthcare) were applied to the plate and 10 μl of the agent to be tested was 
applied to each disc. The plates were incubated for 24 h at 37°C, 5% CO2 and then the 
diameter of growth inhibition was recorded. At least three plates were prepared for each 
agent tested, and we measured the growth inhibition zone twice for each disc. Each 
experiment was performed at least two times on different days. The results were averaged, 
and the error bars represent the standard deviation of the mean. All the agents tested were 
obtained from Sigma-Aldrich. 
 
6.14 In vivo infant rat model 
The infant rat model was used as previously described (293). Briefly, bacteria were grown to 
mid-log phase in GC medium, washed, and resuspended at the desired concentration in PBS. 
Six to eight-day-old pups from litters of outbred Wistar rats (Charles River) were challenged 
intraperitoneally with the 2996 wild-type and the isogenic knockout mutant strains at a 1:1 
ratio to establish mixed infections. Groups of infant rats were used for each infectious dose 
of 4.5 x 10
3
 or 4.5 x 10
4
 CFUs respectively. A control group of 9 infant rats was injected 
with PBS. After 18h post bacterial challenge, blood samples were obtained by cheek 
puncture, and aliquots (100 μl of undiluted sera as well as 1/10 and 1/100 dilutions) were 
plated onto columbia agar supplemented with 5% horse blood with or without kanamycin for 
viable cell counting. The number of CFU/ml found in blood was determined after overnight 
incubation of the plates at 37 ◦C in a 5% CO2 atmosphere. Enumeration of wild-type 
bacteria and mutant bacteria allowed to determine the competitive index (CI) ratio using the 
following formula: CI=(WT output/mutant output)/(WT input/mutant input). Observed CIs 
from the two infectious doses follow the same statistical distribution and were pooled to 
increase the power of the analysis. Statistical significance was assessed with the Mann-
Whitney test. 
 
71 
 
6.15 Ethics statement 
All animal trials were carried out in compliance with current Italian legislation on the care 
and use of animals in experimentation (Legislative Decree 116/92) and with the Novartis 
Animal Welfare Policy and Standards. Protocols were approved by the Italian Ministry of 
Health (Authorization D.M. n. 166/2012 - B) and by the local Novartis Animal Welfare 
Body (Research Project AWB 201202). Following infection, animals were clinically 
monitored daily for criteria related to their ability to feed, reactivity and motility, and 
cutaneous redness. After 18 hours all animals were alive and normally reactive, and were 
euthanized by cervical dislocation, as pre-established in agreement with Novartis Animal 
Welfare Policies. 
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 Table 3 Plasmids and strains used in this study. 
 
  
Name Description Antibiotic resistance Reference
pGEMT Cloning vector Ampicillin Promega
pGEMT-hexRKO::Kan Plasmid for deletion of Nm hexR  gene by homologous recombination Ampicillin, Kanamycin This study
pGEMT-Pzwf Plasmid harboring 321 bp promoter fragment upstream of zwf  gene Ampicillin This study
pGEMT-Pedd Plasmid harboring 386 bp promoter fragment upstream of edd  gene Ampicillin This study
pGEMT-FLA-s17 pGEMT containing the flanking region of sRNA0899-0900 with a BamHI site in the middle Ampicillin This study
pGEMT-s17KO::Ery pGEMT-FLA-s17 derivative in which a 1200bp Ery cassette was cloned as a BamHI fragment between flanking regions Ampicillin, Erythromycin This study
pGEMT-FLA-s27 pGEMT containing the flanking region of sRNA1400-1401 with a BamHI site in the middle Ampicillin This study
pGEMT-s27KO::Ery pGEMT-FLA-s27 derivative in which a 1200bp Ery cassette was cloned as a BamHI fragment between flanking regions Ampicillin, Erythromycin This study
pGEMT-FLA-s38 pGEMT containing the flanking region of sRNA1923-1924 with a BamHI site in the middle Ampicillin This study
pGEMT-s38KO::Ery pGEMT-FLA-s38 derivative in which a 1200bp Ery cassette was cloned as a BamHI fragment between flanking regions Ampicillin, Erythromycin This study
pGEMT-FLA-SRS3 pGEMT containing the flanking region of sRNA1880-1801 with a BamHI site in the middle Ampicillin This study
pGEMT-SRS3::Ery pGEMT-FLA-SRS3 derivative in which a 1200bp Ery cassette was cloned as a BamHI fragment between flanking regions Ampicillin, Erythromycin This study
pGEMT-FLA-1880 pGEMT containing the flanking regions of NMB1880 and sRNA1880-1881 with a BamHI site in the middle Ampicillin This study
pGEMT-1880KO::Ery pGEMT-FLA-1880 derivative  in which a 1200bp Ery cassette was cloned as a BamHI fragment between flanking regions Ampicillin, Erythromycin This study
pBluescript (pBS-KS) Cloning vector Ampicillin Novagen
pBS-KS-FLA-IG26 pBS-KS containing the flanking region of sRNA0898-0899 with a XmaI site in the middle Ampicillin This study
pBS-KS-IG26::Ery pBS-KS-FLA-IG26 derivative in which a 1200bp Ery cassette was cloned as a XmaI fragment between flanking regions Ampicillin, Erythromycin This study
pBS-KS-FLA-BNS1 pBS-KS containing the flanking region of BNS1 with a XmaI site in the middle Ampicillin This study
pBS-KS-BNS1::Ery pBS-KS-FLA-BNS1 derivative in which a 1200bp Ery cassette was cloned as a XmaI fragment between flanking regions Ampicillin, Erythromycin This study
pBS-KS-FLA-BNS2 pBS-KS containing the flanking region of BNS2 with a XmaI site in the middle Ampicillin This study
pBS-KS-BNS2::Ery pBS-KS-FLA-BNS2 derivative in which a 1200bp Ery cassette was cloned as a XmaI fragment between flanking regions Ampicillin, Erythromycin This study
pMK Cloning vector Kanamycin Life Technologies
pMK-sRNAwt Vector harboring one copy of sRNA1880-1881, derived from in vitro  synthesis Kanamycin This study
pMK-sRNAmutP Vector harboring one copy of sRNA1880-1881 with mutations disrupting its promoter sequence, derived from in vitro  synthesis Kanamycin This study
pMK-sRNAmutGC
Vector harboring one copy of sRNA1880-1881 with mutations disrupting pairing of its GC-rich stretches, derived from in vitro 
synthesis
Kanamycin This study
pET15b(+) Plasmid for inducible expression of histidine-tagged recombinant proteins in E. coli Ampicillin Life Technologies
pET15b(+)-hexR Plasmid for expression and purification of histidine-tagged HexR in E. coli Ampicillin This study
pComCmrPind
Plasmid for allelic replacement at a chromosomal location between ORFs NMB1428 and NMB1429 and inducible expression 
under the control of the P tac  promoter and the lacI  repressor
Ampicillin, Chloramphenicol Ieva et al., J Bacteriol 2005
pComCmrPind-hexR Plasmid for complementation of HexR null mutant, derivative of pComCmrP ind containing a copy of hexR  gene Ampicillin, Chloramphenicol This study
pCOM1880-Pind-null 
Plasmid for complementation of NMB1880 + sRNA1880-1881 null mutant, derivative of pComCmrP ind containing a copy of 
NMB1880 gene and no copy of sRNA1880-1881
Ampicillin, Chloramphenicol This study
pCOM1880-Pind-sRNAwt
Plasmid for complementation of NMB1880 + sRNA1880-1881 null mutant, derivative of pComCmrP ind containing a copy of 
NMB1880 gene and one copy of sRNA1880-1881
Ampicillin, Chloramphenicol This study
pCOM1880-Pind-sRNAmutP
Plasmid for complementation of NMB1880 + sRNA1880-1881 null mutant, derivative of pComCmrP ind containing a copy of 
NMB1880 gene and one copy of sRNA1880-1881 with mutations disrupting its promoter sequence
Ampicillin, Chloramphenicol This study
pCOM1880-Pind-sRNAmutGC
Plasmid for complementation of NMB1880 + sRNA1880-1881 null mutant, derivative of pComCmrP ind containing a copy of 
NMB1880 gene and one copy of sRNA1880-1881 with mutations disrupting pairing of its GC-rich stretches
Ampicillin, Chloramphenicol This study
MC58 Nm  laboratory-adapted reference strain - Tettelin et al., Science 2000
MC58 ΔFur MC58 derivative, lacking fur  gene Kanamycin Delany et al., J Bacteriol 2003
MC58 Δhfq MC58 derivative, lacking hfq  gene Chloramphenicol Fantappiè et al., Infect Immun 2009
MC58 ΔhexR MC58 derivative, lacking hexR  gene Kanamycin This study
MC58 ΔhexR c-hexR MC58 derivative, lacking hexR  gene, with a copy of  hexR  reintroduced out-of-locus under control of inducible P tac promoter Kanamycin, Chloramphenicol This study
MC58 ΔsRNA1880-1881 MC58 derivative, lacking sRNA1880-1881 Erythromycin This study
MC58 1880KO MC58 derivative, lacking NMB1880 gene and sRNA1880-1881 Erythromycin This study
MC58 sRNAnull MC58 derivative, with the NMB1880 gene under control of inducible P tac promoter, no sRNA in NMB1880-1881 IGR Chloramphenicol This study
MC58 sRNAwt MC58 derivative, with the NMB1880 gene under control of inducible P tac promoter, one wt copy of sRNA in NMB1880-1881 IGR Chloramphenicol This study
MC58 sRNAmutP
MC58 derivative, with the NMB1880 gene under control of inducible P tac promoter, one copy of sRNA in NMB1880-1881 IGR 
with mutations disrupting its promoter sequence
Chloramphenicol This study
MC58 sRNAmutGC
MC58 derivative, with the NMB1880 gene under control of inducible P tac promoter, one copy of sRNA in NMB1880-1881 IGR 
with mutations disrupting pairing of its GC-rich stretches
Chloramphenicol This study
2996 Clinical isolate - Comanducci et al., J Exp Med. 2002
2996 ΔsRNA0898-0899 2996 derivative, lacking sRNA0898-0899 Erythromycin This study
2996 ΔsRNA0899-0900 2996 derivative, lacking sRNA0899-0900 Erythromycin This study
2996 ΔsRNA1400-1401 2996 derivative, lacking sRNA1400-1401 Erythromycin This study
2996 ΔBNS1 2996 derivative, lacking BNS1 Kanamycin This study
2996 ΔsRNA1923-1924 2996 derivative, lacking sRNA1923-1924 Erythromycin This study
2996 ΔBNS2 2996 derivative, lacking BNS2 Erythromycin This study
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Table 4 Oligonucleotides used in this study. 
 
 
 
a: underscored letters indicate restriction enzyme sites. 
 
Name Sequence
a
Restriction Sites Application
Hex-R1 ATTCG TCTAGA GGTTTCGTCGTTGATGCGGTTTTTG XbaI
Hex-R2 CAAATGGTTCG GGATCC GTTGCCACACAGGAAAATG BamHI
Hex-R3 CTGTGTGGCAAC GGATCC CGAACCATTTGGGTTCCGC BamHI
Hex-R4 ATTCG AAGCTT TCACGGAAAAGGCTTTGAGC HindIII
GG006 ATATCATATGTTAAGCAAAATCAGCGAATCACTG NdeI
GG007 ATATATGCATTCAATCTTTGTCGTAATCGATGTGC NsiI
GG012 CTGTACTTCCAGGGCTTAAGCAAAATCAGCGAATCACTG -
GG013 AATTAAGTCGCGTTAATCTTTGTCGTAATCGATGTGC -
GG034 CTCGAGCGTCTGAAAGTGGGAAGCGG XhoI
GG035 GGATCCGTACTCATCGTATTATCTCGTCAGG BamHI
GG036 CTCGAGCCCCTATTCCGTTACAACAATCG XhoI
GG037 GGATCCTTCACGGTCGGTCTCCTGTC BamHI
0089RT-F GAAACGATGCTGGTGGAAC -
0089RT-R CCGCTGGTAATGATGTATTGG -
0207RT-F TGACCAAATTCGACACCGT -
0207RT-R ATCGACACCGAGTTCTTTCC -
0334RT-F ATTTTGATTGACCGCCTCAC -
0334RT-R CACTGATCGAAGGGGTTGAC -
0663RT-F TATGCCGTTACCCCGAATGT -
0663RT-R CAGTGTTGACTTTGCCGATG -
1389RT-F ATGGTTTCCCGCCTCTTG -
1389RT-R CGATGTGCTTGTTGTGTATGCT -
1392RT-F AGCCTGTGAAAACCTTGCTG -
1392RT-R TTGATTTGCTGGGAAGAAGC -
1393RT-F TTGAAAAGCGAAATGGGTTC -
1393RT-R GGTGTAAGGGTGGACGAAGG -
1476RT-F ACGTTGCCATTTACAACGAA -
1476RT-R GTTCGGCGTTGGTAATTTCT -
1710RT-F GCAAATGAGTTCCGCCATC -
1710RT-R ATAGGCAGGGTGGTCAAGG -
1968RT-F TCAAACAAGGTGCGAAATTG -
1968RT-R CCATACTGTTGTCGGTGTCG -
2159RT-F GTTATCTCCGCCGCTTCCT -
2159RT-R GCTGTTGGGCACGATGTT -
1880RT-F ATTGAAGGCGCAGATTGAC -
1880RT-R CGTGTATCCAACTTGCCAAC -
1881RT-F ACGGATACAGCGACAAAGTG -
1881RT-R CTCGCGTATCGTCATGCT -
1882RT-F CAACGACGGCTACACTGTTT -
1882RT-R CATTTGTTGCGATGTGATGA -
RT-SRS3NEW-F GACTGCCATCGGTCTGAATC -
RT-SRS3NEW-R CTCCGTTTTAGCTTCGCAGA -
16SRT-F ACGTAGGGTGCGAGCGTTAATC -
16SRT-R CTGCCTTCGCCATCGGTATTCCT -
hexR  KO
hexR  complementation
PIPE cloning of hexR
zwf  promoter probe
edd  promoter probe
qRT-PCR
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Table 4 (continued) Oligonucleotides used in this study. 
 
 
  
a: underscored letters indicate restriction enzyme sites.  
Name Sequence
a
Restriction Sites Application
nrrF-NB GTATGTCTCGTATATGCCGACTCCAAGTGTGAAAGTGATGATGGGGAAAT - NrrF NB
1205-3 GGCAGCCACACCCAAACAC - AniS NB
sRNA10-R CCAGCTTGATATACTCGGCGGAT - sRNA0837-0838 NB
SRS19-R4 GAATAAATATGTCCCATTGTCATCCCCTTAAGCTGATG - sRNA0898-0899 NB
sRNA17-R2 ATCGTGTGGATATACGCTGTTTGTCAGGTGTTTTCAAGCACCGTGGGAAA - sRNA0899-0900 NB
GG075 GCTCCATAAGACATAATCAACTGTG - sRNA1400-1401 NB
Bns1_p  CCTCCCGAATATATCTGCCTGCTGTTTCCTCTTTATTCAG - BNS1 NB
GG052 cacccgagtttatgcggcaaacagcg -
GG054 ttaacttcgttgaagctgcgatttcagaagct -
GG087 AGTATGAATGGTCAATACATTGCGG - sRNA1923-1924 NB
SRS17-R4 CACATTACGGGGAAAACGTTTTACTCAATGAG - BNS2 NB
UP_IG26F  GCTCTAGAGAAACAGGCACAACGGCAAA             XbaI
UP_IG26R  TCCCCCGGGCTTAAATCGCCCGTTAAGGC         XmaI
DW_IG26F TCCCCCGGGTTTATTTTCAACATCAGCTTAAGG   XmaI
DW_IG26R CCGCTCGAGCTTTTTCTTCCATTTTCGGGCT         XhoI
FLA-UP17F CGAATACTCCATGCTGTTACGTG                                      -
FLA-UP17R TTTCTGCAAGCGGATCCGGAAATGTGTCAAGAGAATTAGCCC BamHI
FLA-DO17F GACACATTTCCGGATCCGCTTGCAGAAAATAGAAAGATTGG   BamHI
FLA-DO17R CACGATAACTATTTGATTTGCTTCCG                                 -
flaUP1400F CCAAAGATTTGGCGGCTAACAGCC -
flaUP1400R GTCCCGACAGCGGATCCATATACAGATATTTCAGGCTGCCTG BamHI
flaDO1401F TATCTGTATATGGATCCGCTGTCGGGACGGTGTGCCGAAG BamHI
flaDO1401R TTCGGCAGTCCTGTTCTACCGC -
UP_bns1F GCTCTAGACGACAATCTTGTCGTGCG XbaI
UP_bns1R TCCCCCGGGGAGAATCCCGTTATTTTAAG XmaI
DW_bns1F TCCCCCGGGCTTCAGACGGTATCAGCC XmaI
DW_bns1R CCGCTCGAGCCGTTTTGTCCATATTTCTGC XhoI
GG103 GCGGTTGGCAAGTTGGATACAC -
GG104 GGATCCttgaaaccgcactttagcttcgc BamHI
GG105 gcggtttcaaGGATCCaaagcagcctgcaacgaagcc BamHI
GG106 CGGACGGGTCGGACAACTC -
flaUP1923F TTGTACTGTCTTCGGCTTCGTCG -
flaUP1923R AAACCAATAGGGGATCCGCACGTTGAAAATGCCGTCTGAAC BamHI
flaDO1924F TTTCAACGTGCGGATCCCCTATTGGTTTTCCCGTATCCAC BamHI
flaDO1924R GTCGATCCGATAGACGGGACGAAC -
UP_bns2F GCTCTAGACGCCTGAAACGCATCAACC XbaI
UP_bns2R TCCCCCGGGGATGCCGTCTGAAACGGC XmaI
DW_bns2F TCCCCCGGGGTTCCATCGGATAAAAGGC XmaI
DW_bns2R CCGCTCGAGGATGGTGCTGTAAATGGACG XhoI
GG149 TTAAAAAGGCAGAACCCGTTGCG -
GG150 AGGTGCTGTTTCAGGTTGATGG -
GG172 GGCTTACCGCCCTCTCCCTAAC -
GG173 CGAATTGAAAAGCAGCCTGTATGTTG -
GG180 aaCCCGGGGCGTTTTGCGCCAGCCGTTGCAG XmaI
GG181 GGATCCATGAACACCGCCGCCATCTACCG BamHI
GG186 CGGTGTTCATGGATCCACCCAACCCATAGGAGAACCCCATG BamHI
GG188 aaACTAGTTCTGAAACAGAAACATCGGCCTG SpeI
GG185 aaTCTAGAATGAACACCGCCGCCATCTACCG XbaI
GG187 aaATGCATACCCAACCCATAGGAGAACCCCATG NsiI
GG189 aaCATATGAAACCGCGTTTTTATTGGGCAGC NdeI
GG190 aaATGCATaaaCTCGAGCTACTTTTTCCCCGCCGCAACGG NsiI, XhoI
sRNA0899-0900 KO
sRNA1400-1401 KO
BNS1 KO
sRNA1923-1924 KO
BNS2 KO
sRNA1880-1881 KO
Isogenic mutants of 
NMB1880-1881-1882 operon 
and sRNA
sRNA0898-0899 KO
sRNA1880-1881 NB
Sequencing of NMB1880-
1881 IGR
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